<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Sedatives for opioid withdrawal in newborn infants - Zankl, A - 2021 | Cochrane Library</title> <meta content="Sedatives for opioid withdrawal in newborn infants - Zankl, A - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002053.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Sedatives for opioid withdrawal in newborn infants - Zankl, A - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002053.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002053.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Sedatives for opioid withdrawal in newborn infants" name="citation_title"/> <meta content="Angelika Zankl" name="citation_author"/> <meta content="angelika.zankl@gmail.com" name="citation_author_email"/> <meta content="Jill Martin" name="citation_author"/> <meta content="Royal Prince Alfred Hospital" name="citation_author_institution"/> <meta content="Jane G Davey" name="citation_author"/> <meta content="RPA Women and Babies, Royal Prince Alfred Hospital" name="citation_author_institution"/> <meta content="David A Osborn" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD002053.pub4" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/05/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002053.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002053.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002053.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; Chlorpromazine [therapeutic use]; Clonidine [therapeutic use]; Diazepam [therapeutic use]; Hypnotics and Sedatives [*therapeutic use]; Narcotics [therapeutic use]; Neonatal Abstinence Syndrome [*drug therapy]; Opioid-Related Disorders [*drug therapy]; Phenobarbital [therapeutic use]; Randomized Controlled Trials as Topic; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002053.pub4&amp;doi=10.1002/14651858.CD002053.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="IregKd2C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002053\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002053\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","th","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002053.pub4",title:"Sedatives for opioid withdrawal in newborn infants",firstPublishedDate:"May 18, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002053.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002053.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002053.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002053.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002053.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002053.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002053.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002053.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002053.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002053.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3451 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002053.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-sec-0121"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-sec-0107"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/appendices#CD002053-sec-0126"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/supinfo/CD002053StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/supinfo/CD002053StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Sedatives for opioid withdrawal in newborn infants</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/information#CD002053-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Angelika Zankl</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/information#CD002053-cr-0005">Jill Martin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/information#CD002053-cr-0006">Jane G Davey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002053.pub4/information#CD002053-cr-0007">David A Osborn</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/information/en#CD002053-sec-0143">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 May 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002053.pub4">https://doi.org/10.1002/14651858.CD002053.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002053-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002053-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002053-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002053-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002053-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD002053-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002053-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002053-abs-0001" lang="en"> <section id="CD002053-sec-0001"> <h3 class="title" id="CD002053-sec-0001">Background</h3> <p>Neonatal abstinence syndrome (NAS) due to opioid withdrawal may result in disruption of the mother–infant relationship, sleep–wake abnormalities, feeding difficulties, weight loss, seizures and neurodevelopmental problems. </p> </section> <section id="CD002053-sec-0002"> <h3 class="title" id="CD002053-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of using a sedative versus control (placebo, usual treatment or non‐pharmacological treatment) for NAS due to withdrawal from opioids and determine which type of sedative is most effective and safe for NAS due to withdrawal from opioids. </p> </section> <section id="CD002053-sec-0003"> <h3 class="title" id="CD002053-sec-0003">Search methods</h3> <p>We ran an updated search on 17 September 2020 in CENTRAL via CRS Web and MEDLINE via Ovid. We searched clinical trials databases, conference proceedings and the reference lists of retrieved articles for randomised controlled trials and quasi‐randomised trials<b>.</b> </p> </section> <section id="CD002053-sec-0004"> <h3 class="title" id="CD002053-sec-0004">Selection criteria</h3> <p>We included trials enrolling infants with NAS born to mothers with an opioid dependence with more than 80% follow‐up and using randomised, quasi‐randomised and cluster‐randomised allocation to sedative or control. </p> </section> <section id="CD002053-sec-0005"> <h3 class="title" id="CD002053-sec-0005">Data collection and analysis</h3> <p>Three review authors assessed trial eligibility and risk of bias, and independently extracted data. We used the GRADE approach to assess the certainty of the evidence. </p> </section> <section id="CD002053-sec-0006"> <h3 class="title" id="CD002053-sec-0006">Main results</h3> <p>We included 10 trials (581 infants) with NAS secondary to maternal opioid use in pregnancy. There were multiple comparisons of different sedatives and regimens. There were limited data available for use in sensitivity analysis of studies at low risk of bias. </p> <p><b>Phenobarbital versus supportive care: </b>one study reported there may be little or no difference in treatment failure with phenobarbital and supportive care versus supportive care alone (risk ratio (RR) 2.73, 95% confidence interval (CI) 0.94 to 7.94; 62 participants; very low‐certainty evidence). No infant had a clinical seizure. The study did not report mortality, neurodevelopmental disability and adverse events. There may be an increase in days' hospitalisation and treatment from use of phenobarbital (hospitalisation: mean difference (MD) 20.80, 95% CI 13.64 to 27.96; treatment: MD 17.90, 95% CI 11.98 to 23.82; both 62 participants; very low‐certainty evidence). </p> <p><b>Phenobarbital versus diazepam: </b>there may be a reduction in treatment failure with phenobarbital versus diazepam (RR 0.39, 95% CI 0.24 to 0.62; 139 participants; 2 studies; low‐certainty evidence). The studies did not report mortality, neurodevelopmental disability and adverse events. One study reported there may be little or no difference in days' hospitalisation and treatment (hospitalisation: MD 3.89, 95% CI –1.20 to 8.98; 32 participants; treatment: MD 4.30, 95% CI –0.73 to 9.33; 31 participants; both low‐certainty evidence). </p> <p><b>Phenobarbital versus chlorpromazine:</b> there may be a reduction in treatment failure with phenobarbital versus chlorpromazine (RR 0.55, 95% CI 0.33 to 0.92; 138 participants; 2 studies; very low‐certainty evidence), and no infant had a seizure. The studies did not report mortality and neurodevelopmental disability. One study reported there may be little or no difference in days' hospitalisation (MD 7.00, 95% CI –3.51 to 17.51; 87 participants; low‐certainty evidence) and 0/100 infants had an adverse event. </p> <p><b>Phenobarbital and opioid versus opioid alone:</b> one study reported no infants with treatment failure and no clinical seizures in either group (low‐certainty evidence). The study did not report mortality, neurodevelopmental disability and adverse events. One study reported there may be a reduction in days' hospitalisation for infants treated with phenobarbital and opioid (MD –43.50, 95% CI –59.18 to –27.82; 20 participants; low‐certainty evidence). </p> <p><b>Clonidine and opioid versus opioid alone:</b> one study reported there may be little or no difference in treatment failure with clonidine and dilute tincture of opium (DTO) versus DTO alone (RR 0.09, 95% CI 0.01 to 1.59; 80 participants; very low‐certainty evidence). All five infants with treatment failure were in the DTO group. There may be little or no difference in seizures (RR 0.14, 95% CI 0.01 to 2.68; 80 participants; very low‐certainty evidence). All three infants with seizures were in the DTO group. There may be little or no difference in mortality after discharge (RR 7.00, 95% CI 0.37 to 131.28; 80 participants; very low‐certainty evidence). All three deaths were in the clonidine and DTO group. The study did not report neurodevelopmental disability. There may be little or no difference in days' treatment (MD –4.00, 95% CI –8.33 to 0.33; 80 participants; very low‐certainty evidence). One adverse event occurred in the clonidine and DTO group. There may be little or no difference in rebound NAS after stopping treatment, although all seven cases were in the clonidine and DTO group. </p> <p><b>Clonidine and opioid versus phenobarbital and opioid:</b> there may be little or no difference in treatment failure (RR 2.27, 95% CI 0.98 to 5.25; 2 studies, 93 participants; very low‐certainty evidence). One study reported one infant in the clonidine and morphine group had a seizure, and there were no infant mortalities. The studies did not report neurodevelopmental disability. There may be an increase in days' hospitalisation and days' treatment with clonidine and opioid versus phenobarbital and opioid(hospitalisation: MD 7.13, 95% CI 6.38 to 7.88; treatment: MD 7.57, 95% CI 3.97 to 11.17; both 2 studies, 91 participants; low‐certainty evidence). There may be little or no difference in adverse events (RR 1.55, 95% CI 0.44 to 5.40; 2 studies, 93 participants; very low‐certainty evidence). However, there was oversedation only in the phenobarbital and morphine group; and hypotension, rebound hypertension and rebound NAS only in the clonidine and morphine group. </p> </section> <section id="CD002053-sec-0007"> <h3 class="title" id="CD002053-sec-0007">Authors' conclusions</h3> <p>There is very low‐certainty evidence that phenobarbital increases duration of hospitalisation and treatment, but reduces days to regain birthweight and duration of supportive care each day compared to supportive care alone. There is low‐certainty evidence that phenobarbital reduces treatment failure compared to diazepam and very low‐certainty evidence that  phenobarbital reduces treatment failure compared to chlorpromazine. There is low‐certainty evidence of an increase in days' hospitalisation and days' treatment with clonidine and opioid compared to phenobarbital and opioid. There are insufficient data to determine the safety and incidence of adverse events for infants treated with combinations of opioids and sedatives including phenobarbital and clonidine. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002053-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002053-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD002053-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD002053-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002053-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002053-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002053-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002053-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002053-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD002053-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002053-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002053-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002053-abs-0002" lang="en"> <h3>Sedatives for opioid withdrawal in newborn infants</h3> <p><b>Review question</b> </p> <p>To determine the effectiveness and safety of using a sedative (sleep‐inducing medicine) compared to a non‐opioid or a non‐medicine control for the treatment of neonatal abstinence syndrome (NAS) due to withdrawal from opioids. </p> <p><b>Background</b> </p> <p>Use of opioids (prescribed or illicit) by pregnant women may result in their newborn infant experiencing withdrawal symptoms collectively referred to as NAS, which may result in disruption of the mother–infant relationship, sleeping and feeding difficulties, weight loss and seizures (fits). Treatments for newborn infants used to ameliorate NAS and reduce complications include supportive treatments such as a dummy (pacifier); swaddling or close wrapping; small frequent feeds; close skin contact by carrying in sling and other methods; and prescription of opioids or sedatives, or both. </p> <p><b>Study characteristics</b> </p> <p>The search was up‐to‐date to September 2020.</p> <p><b>Key results</b> </p> <p>We included 10 trials, enrolling 581 infants with NAS caused by maternal opioid use in pregnancy, in the review. There were multiple comparisons of different sedatives and regimens. The addition of phenobarbital to supportive care increased duration of hospitalisation and treatment, but reduced duration supportive care each day compared to supportive care alone. Phenobarbital reduced treatment failure compared to both diazepam and chlorpromazine. Clonidine and opioid compared to phenobarbital and opioid increased in days of hospitalisation and days of treatment. There were insufficient data to determine the safety and incidence of side effects for infants treated with combinations of opioids and sedatives including phenobarbital and clonidine. Side effects reported in infants treated with an opioid included oversedation from the addition of phenobarbital, and low blood pressure from the addition of clonidine with rebound high blood pressure and NAS reported after stopping clonidine. We found one ongoing study of clonidine plus morphine for NAS. </p> <p><b>Certainty of the evidence</b> </p> <p>This was low to very low for all results.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002053-sec-0121" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002053-sec-0121"></div> <h3 class="title" id="CD002053-sec-0122">Implications for practice</h3> <section id="CD002053-sec-0122"> <p>This review should be considered in the context of the associated review 'Opioid treatment for opioid withdrawal in newborn infants,' which found moderate‐certainty evidence that use of an opioid reduces treatment failure compared to phenobarbital, and low‐certainty evidence that use of an opioid reduces treatment failure compared to diazepam or chlorpromazine (<a href="./references#CD002053-bbs2-0127" title="ZanklA , MartinJ , DaveyJG , OsbornDA . Opioid treatment for opioid withdrawal in newborn infants. Cochrane Database of Systematic Reviews (in press).">Zankl 2021</a>).  </p> <p>There are insufficient data to determine the effectiveness and safety of non‐pharmacological interventions as an alternative to the addition of a pharmacological agent for neonatal abstinence syndrome (NAS) secondary to opioids. There is very low‐certainty evidence that the addition of phenobarbital may increases duration of hospitalisation and treatment, but reduces days to regain birthweight and duration of supportive care each day compared to supportive care alone. </p> <p>There is low‐certainty evidence that phenobarbital may reduce treatment failure compared to diazepam and very low‐certainty evidence that phenobarbital may reduce treatment failure compared to chlorpromazine. </p> <p>There is low‐certainty evidence of an increase in days' hospitalisation and days' treatment from use of clonidine and opioid compared to phenobarbital and opioid. There are insufficient data to determine the safety and incidence of adverse events of infants treated with combinations of opioids and sedatives including phenobarbital and clonidine.  </p> </section> <h3 class="title" id="CD002053-sec-0123">Implications for research</h3> <section id="CD002053-sec-0123"> <p>Trials of non‐pharmacological interventions (including the eat, sleep, console intervention) for reducing separation of mother and infant, admission to the nursery and pharmacological treatment of NAS are needed. </p> <p>Adequately powered trials of the addition of phenobarbital to opioid therapy for NAS are needed to determine if severity and duration of NAS are reduced without adverse effects including oversedation. </p> <p>Current trials of clonidine versus morphine (<a href="./references#CD002053-bbs2-0013" title="BadaHS , SithisarnT , GibsonJ , GarlitzK , CaldwellR , CapiloutoG , et al. Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics2015;135(2):e383-91. [DOI: 10.1542/peds.2014-2377] [PMID: 25624389]">Bada 2015</a>), adjunctive clonidine versus phenobarbital in infants who failed morphine treatment (<a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a>), and adjunctive clonidine versus phenobarbital in infants concomitantly treated with morphine (<a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>) have used clonidine doses 5 μg/kg/day or 6 μg/kg/day titrated to 12 μg/kg/day. One small trial of clonidine (titrated from 6 μg/kg/day to 12 μg/kg/day) versus placebo in morphine‐treated infants is ongoing (<a href="./references#CD002053-bbs2-0045" title="NCT03762317. Clonidine as adjunct to morphine for neonatal abstinence syndrome [Clonidine as adjunct to morphine in the management of term and near term infants with neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT03762317 (first received 3 December 2018). ">NCT03762317</a>). Trials to determine optimal dosing strategies (dose, timing and duration) of clonidine are needed. Dose‐escalation studies should assess time to control of NAS (control of symptoms or reduction of NAS score to a clinically 'safe' level); severity and duration of withdrawal; infant feeding; weight loss and gain; and adverse effects including hypotension, rebound hypertension and rebound NAS after cessation of clonidine. </p> <p>Future trials should measure the outcomes prespecified in this review, and be powered to detect important adverse events including seizures, oversedation, hypotension, rebound hypertension, rebound NAS and infant mortality. Trials are needed that measure psychosocial (mother–infant interaction, out‐of‐home care), growth and neurodevelopmental outcomes using validated scales of infant development. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002053-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002053-sec-0008"></div> <div class="table" id="CD002053-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Phenobarbital versus supportive care for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital vs supportive care for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal </p> <p><b>Settings:</b> hospital, Australia </p> <p><b>Intervention:</b> phenobarbital vs supportive care </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Supportive care</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Phenobarbital</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.73</b> <br/>(0.94 to 7.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>62<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>321 per 1000</b><br/>(111 to 934) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal and infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 14.0 days (9.9 to 18.1)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' hospitalisation was <b>20.8 higher</b> (13.64 to 27.96 higher) in the phenobarbital group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' pharmacological treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 8.6 days (5.6 to 11.6)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' treatment was <b>17.9 higher</b> (11.98 to 23.82 higher) in the phenobarbital group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious risk of bias (quasi‐random allocation, no blinding).<br/><sup>b</sup>Downgraded one level for serious imprecision (wide confidence intervals).<br/><sup>c</sup>No events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002053-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Phenobarbital versus diazepam for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital vs diazepam for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, USA<br/><b>Intervention:</b> phenobarbital vs diazepam </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Diazepam</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Phenobarbital</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b><br/>(93 to 241) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.39</b> <br/>(0.24 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/>  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal and infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 16.8 days (14.2 to 19.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' hospitalisation was <b>3.89 higher</b> (1.2 lower to 8.98 higher) in the phenobarbital group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' pharmacological treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 10.2 days (7.8 to 12.6)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' treatment was <b>4.3 higher</b> (0.73 lower to 9.33 higher) in the phenobarbital group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (high‐risk allocation procedures).<br/><sup>b</sup>Downgraded one level for serious inconsistency (moderate heterogeneity).<br/><sup>c</sup>Downgraded one level for serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002053-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Phenobarbital versus chlorpromazine for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital vs chlorpromazine for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b>  hospital, USA and Switzerland<br/><b>Intervention:</b> phenobarbital vs chlorpromazine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Chlorpromazine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Phenobarbital</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>357 per 1000</b><br/>(219 to 587) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.55</b><br/>(0.33 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal and infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 25.0 days (16.1 to 33.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' hospitalisation was <b>7 higher</b> (3.51 lower to 17.51 higher) in the phenobarbital group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup><sup>,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' pharmacological treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/>  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (single study at low risk of bias).<br/><sup>b</sup>Downgraded one level for serious inconsistency (high heterogeneity).<br/><sup>c</sup>Downgraded one level for serious imprecision (wide confidence intervals).<br/><sup>d</sup>Downgraded two levels for very serious imprecision (no events).<br/><sup>e</sup>Downgraded one level for serious risk of bias (incomplete outcome data). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002053-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Phenobarbital and opioid versus opioid alone for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital and opioid vs opioid alone for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b>  hospital, USA<br/><b>Intervention:</b> phenobarbital and opioid vs opioid alone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>D<b>ilute tincture of opium</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Phenobarbital and dilute tincture of opium</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal and infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 80.8 days (66.8 to 94.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' hospitalisation was <b>43.5 lower</b> (59.18 to 27.82 lower) in the phenobarbital and dilute tincture of opium group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' pharmacological treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/>  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (high‐risk allocation procedures).<br/><sup>b</sup>Downgraded two levels for very serious imprecision (single small study, no events).<br/><sup>c</sup>Downgraded one level for serious imprecision (single small study, wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002053-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Clonidine and opioid versus opioid alone for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clonidine and opioid vs opioid alone for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b>  hospital, USA<br/><b>Intervention:</b> clonidine and opioid vs opioid alone (all infants) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>D<b>ilute tincture of opium</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Clonidine and dilute tincture of opium</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/>(1 to 199) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.09</b> <br/>(0.01 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b><br/>(1 to 201) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.14</b> <br/>(0.01 to 2.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality post discharge</b> <br/>Follow‐up: 2 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7</b> <br/>(0.37 to 131.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 infants in the clonidine group died from unrelated causes.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/>  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' pharmacological treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 15.0 days (13.0 to 17.0)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' treatment was <b>4 lower</b> (8.33 lower to 0.33 higher) in the clonidine and dilute tincture of opium group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.00</b><br/>(0.13 to 71.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 infant with supraventricular tachycardia in clonidine group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious inconsistency (single small study).<br/><sup>b</sup>Downgraded two levels for very serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002053-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Clonidine and opioid versus phenobarbital and opioid for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clonidine and opioid vs phenobarbital and opioid for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, USA<br/><b>Intervention:</b> clonidine and opioid vs phenobarbital and opioid </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Phenobarbital and morphine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Clonidine and morphine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b><br/>(87 to 467) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.27</b> <br/>(0.98 to 5.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3</b> <br/>(0.13 to 71.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality to discharge</b> <br/>Follow‐up: 8 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 26.3 days (22.7 to 29.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' hospitalisation was <b>7.13 higher</b> (6.38 to 7.88 higher) in the clonidine and morphine group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' pharmacological treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 24.0 days (20.4 to 27.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' treatment was <b>7.57 higher</b> (3.97 to 11.17 higher) in the clonidine and morphine group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b><br/>(29 to 360) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.55</b> <br/>(0.44 to 5.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported oversedation in 3 infants receiving phenobarbital and morphine.</p> <p>The other study reported 6 infants with hypotension, rebound hypertension (1 infant) and rebound NAS (1 infant) in infants treated with clonidine and morphine. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (no study at low risk of bias).<br/><sup>b</sup>Downgraded two levels for very serious imprecision (very wide confidence intervals).<br/><sup>c</sup>Downgraded two levels for very serious imprecision (single study with no events).<br/><sup>d</sup>Downgraded one level for serious imprecision (single small study with wide confidence intervals).<br/><sup>e</sup>Downgraded one level for serious inconsistency (heterogeneity, I² = 77%). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002053-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002053-sec-0009"></div> <section id="CD002053-sec-0010"> <h3 class="title" id="CD002053-sec-0010">Description of the condition</h3> <p>Opioid use in pregnancy and neonatal abstinence syndrome (NAS) due to opioid withdrawal is currently a significant clinical and social problem. Since the previous review update on this topic (<a href="./references#CD002053-bbs2-0131" title="OsbornDA , JefferyHE , ColeMJ . Sedatives for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2010, Issue 10. Art. No: CD002053. [DOI: 10.1002/14651858.CD002053.pub3]">Osborn 2010</a>), rates of illicit drug use by pregnant women in the USA as reported by the National Household Survey on Drug Abuse have increased from 3.4% in 1999 to 5.4% in 2013, with heroin abuse still being most common (<a href="./references#CD002053-bbs2-0094" title="Office of Applied Statistics, Substance Abuse and Mental Health Administration (SAMHSA). National household survey on drug abuse. 1999. www.datafiles.samhsa.gov/study/national-household-survey-drug-abuse-nhsda-1999-nid13544 (accessed 28 January 2021).">NHSDA 1999</a>; <a href="./references#CD002053-bbs2-0095" title="Substance Abuse and Mental Health Administration (SAMHSA). National household survey on drug abuse. 2013. samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf (accessed 28 January 2021).">NHSDA 2013</a>). Prescription of methadone and buprenorphine are standard maintenance treatments for pregnant women with an opioid addiction (<a href="./references#CD002053-bbs2-0053" title="BroglySB , SaiaKA , WalleyAY , DuHM , SebastianiP . Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. American Journal of Epidemiology2014;180(7):673-86. [DOI: 10.1093/aje/kwu190] [PMID: 25150272]">Brogly 2014</a>; <a href="./references#CD002053-bbs2-0056" title="CoyleMG , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , FisherG . Neonatal neurobehaviour effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. [DOI: 10.1111/j.1360-0443.2012.04040.x] [PMID: 23106928]">Coyle 2012</a>; <a href="./references#CD002053-bbs2-0071" title="JonesHE , KaltenbachK , HeilSH , StineMD , CoyleMD , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363(24):2320-31. [DOI: 10.1056/NEJMoa1005359] [PMID: 21142534]">Jones 2010</a>; <a href="./references#CD002053-bbs2-0080" title="KocherlakotaP . Neonatal abstinence syndrome. Pediatrics2014;134(2):e547-61. [DOI: 10.1542/peds.2013-3524] [PMID: 25070299]">Kocherlakota 2014</a>; <a href="./references#CD002053-bbs2-0109" title="SiuA , RobinsonCA . Neonatal abstinence syndrome: essentials for the practitioner. Journal of Pediatric Pharmacology and Therapeutics2014;19(3):147-55. [DOI: 10.5863/1551-6776-19.3.147] [PMID: 25309144]">Siu 2014</a>). Of growing concern is the use and abuse of prescription opioid analgesic medications by pregnant women for non‐cancer related pain (<a href="./references#CD002053-bbs2-0080" title="KocherlakotaP . Neonatal abstinence syndrome. Pediatrics2014;134(2):e547-61. [DOI: 10.1542/peds.2013-3524] [PMID: 25070299]">Kocherlakota 2014</a>; <a href="./references#CD002053-bbs2-0082" title="KraftWK , StoverNW , DavisJM . Neonatal abstinence syndrome: pharmacologic strategies for the mother and infant. Seminars in Perinatology2016;40(3):203-12. [DOI: 10.1053/j.semperi.2015.12.007] [PMID: 26791055]">Kraft 2016</a>; <a href="./references#CD002053-bbs2-0103" title="PatrickSW , DudleyJ , MartinPR , HarrellFE , WarrenMD , HartmannKE , et al. Prescription opioid epidemic and infant outcomes. Pediatrics2015;135(5):842-50. [DOI: 10.1542/peds.2014-3299] [PMID: 25869370]">Patrick 2015</a>; <a href="./references#CD002053-bbs2-0111" title="StoverMW , DavisJM . Opioids in pregnancy and neonatal abstinence syndrome. Seminars in Perinatology2015;39(7):561-5. [DOI: 10.1053/j.semperi.2015.08.013] [PMID: 26452318]">Stover 2015</a>). The flow on effect of the illicit and prescribed opioid usage rates across the USA by pregnant women is a nationwide increase in admission of newborn infants to neonatal intensive care units for NAS from 0.6% (7 cases per 1000) in 2004 to 4.0% (27 cases per 1000) in 2013 (<a href="./references#CD002053-bbs2-0116" title="ToliaVN , PatrickSW , BennettMM , MurthyK , SousaJ , SmithPB , et al. Increasing incidence of the neonatal abstinence syndrome in the U.S. neonatal ICUs. New England Journal of Medicine2015;372(22):2118-26. [DOI: 10.1056/NEJMsa1500439] [PMID: 25913111]">Tolia 2015</a>). As the reported mean length of stay for infants requiring treatment for NAS in the USA is 16 days, cost estimates of treatment are USD 159,000 to USD 238,000 greater than for healthy infants (<a href="./references#CD002053-bbs2-0104" title="PeltzG , AnandKJ . Long-acting opioids for treating neonatal abstinence syndrome. A high price for a short stay?JAMA2015;314(19):2023-4. [DOI: 10.1001/jama.2015.13537] [PMID: 26469386]">Peltz 2015</a>). These data are reflected outside the USA across several European countries, Canada and Australia (<a href="./references#CD002053-bbs2-0047" title="AllegaertK , van derAnkerJN . Neonatal withdrawal syndrome: reaching epidemic proportions across the globe. Archives of Diseases in Childhood. Fetal and Neonatal Edition2016;10(1):F2-3. [DOI: 10.1136/archdischild-2015-309566] [PMID: 26482412]">Allegaert 2016</a>; <a href="./references#CD002053-bbs2-0050" title="BauchingerS , SapetschnigI , DandaM , SommerC , ReschB , UrlesbergerB , et al. Methods in neonatal abstinence syndrome (NAS): results of a nationwide survey in Austria. Zeitschrift für Geburtshilfe und Neonatologie2015;219(4):185-9. [DOI: 10.1055/s-0035-1545289] [PMID: 26039498]">Bauchinger 2015</a>; <a href="./references#CD002053-bbs2-0054" title="BroglySB , TurnerS , LajkoszK , DaviesG , NewmanA , JohnsonA , et al. Infants born to opioid-dependent women in Ontario, 2002-2014. Journal of Obstetrics and Gynaecology Canada2017;39(3):157-65. [DOI: 10.1016/j.jogc.2016.11.009] [PMID: 28343557]">Brogly 2017</a>; <a href="./references#CD002053-bbs2-0058" title="DaviesH , GilbertR , JohnsonK , PetersenI , NazarethI , O'DonnellM , et al. Neonatal drug withdrawal syndrome: cross country comparison using hospital administrative data in England, the USA, Western Australia and Ontario, Canada. Archives of Disease in Childhood. Fetal and Neonatal Edition2016;101(1):F26-30. [DOI: 10.1136/archdischild-2015-308948] [PMID: 26290479]">Davies 2016</a>; <a href="./references#CD002053-bbs2-0079" title="KirchnerL , Graf-RohmeisterK , Klebermass-SchrehofK , WeningerM , JagschR , MetzV , et al. Neonatal abstinence syndrome in European and North American neonates: differences in clinical characteristics derived from a prospective randomised trial. Klinische Pädiatrie2014;226(5):274-80. [DOI: 10.1055/s-0034-1372586] [PMID: 25062111]">Kirchner 2014</a>; <a href="./references#CD002053-bbs2-0092" title="Australian Institute of Health and Welfare. National Drug Strategy Household Survey detailed report 2013. www.aihw.gov.au/reports/illicit-use-of-drugs/ndshs-2013-detailed/contents/table-of-contents (accessed 28 January 2021).">NDSHS 2013</a>; <a href="./references#CD002053-bbs2-0117" title="TurnerSD , GomesT , CamachoX , YaoZ , GuittmannA , MamdaniMM , et al. Neonatal opioid withdrawal and antenatal prescribing. CMAJ Open2015;3(1):E55-61. [DOI: 10.9778/cmajo.20140065] [PMID: 25844370]">Turner 2015</a>; <a href="./references#CD002053-bbs2-0118" title="UngerA , MetzV , FischerG . Opioid dependent and pregnant: what are the best options for mothers and neonates?Obstetrics and Gynecology International2012;2012:195954. [DOI: 10.1155/2012/195954] [PMID: 22496696]">Unger 2012</a>), indicating that NAS is a globally significant clinical and social problem with concomitant fiscal burdens for healthcare providers. Such is the global concern that the World Health Organization (WHO) has published guidelines for clinicians regarding the management of substance use in pregnancy and NAS (<a href="./references#CD002053-bbs2-0124" title="World Health Organization. Guidelines for the identification and management of substance use and substance use disorders in pregnancy. who.int/iris/bitstream/10665/107130/1/9789241548731_eng.pdf (accessed April 2017).">WHO 2014</a>). </p> <p>Between 48% and 94% of infants exposed to opioids in utero develop clinical signs of withdrawal, with signs of withdrawal from methadone being more common than from heroin (<a href="./references#CD002053-bbs2-0011" title="AlroomiLG , DavidsonJ , EvansTJ , GaleaP , HowatR . Maternal narcotic abuse and the newborn. Archives of Disease in Childhood1988;63(1):81-3. [DOI: 10.1136/adc.63.1.81] [PMID: 3348657]">Alroomi 1988</a>; <a href="./references#CD002053-bbs2-0018" title="DoberczakTM , KandallSR , WiletsI . Neonatal opiate abstinence syndrome in term and preterm infants. Journal of Pediatrics1991;118(6):933-7. [DOI: 10.1016/s0022-3476(05)82214-0] [PMID: 2040931]">Doberczak 1991</a>; <a href="./references#CD002053-bbs2-0061" title="FrickerHS , SegalS . Narcotic addiction, pregnancy, and the newborn. American Journal of Diseases of Children1978;132(4):360-6. [DOI: 10.1001/archpedi.1978.02120290032004] [PMID: 645651]">Fricker 1978</a>; <a href="./references#CD002053-bbs2-0083" title="LamSK , ToWK , DuthieSJ , MaHK . Narcotic addiction in pregnancy with adverse maternal and perinatal outcome. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1992;32(3):216-21. [DOI: 10.1111/j.1479-828x.1992.tb01950.x] [PMID: 1445130]">Lam 1992</a>; <a href="./references#CD002053-bbs2-0086" title="MaasU , KattnerE , Weingart-JesseB , SchaferA , ObladenM . Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. Journal of Perinatal Medicine1990;18(2):111-8. [DOI: 10.1515/jpme.1990.18.2.111] [PMID: 2366131]">Maas 1990</a>; <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002053-bbs2-0098" title="OlofssonM , BuckleyW , AndersenGE , Friis HansenBS . Investigation of 89 children born by drug-dependent mothers. I. Neonatal course. Acta Paediatrica Scandinavica1983;72:403-6. [DOI: 10.1111/j.1651-2227.1983.tb09736.x] [PMID: 6880727]">Olofsson 1983</a>; <a href="./references#CD002053-bbs2-0037" title="OstreaEM , ChavezCJ , StraussME . A study of factors that influence the severity of neonatal narcotic withdrawal. Addictive Diseases1975;2(1-2):187-99. [PMID: 1163362]">Ostrea 1975</a>). Onset of NAS in the case of heroin withdrawal is usually within 24 hours after birth and has a shorter (8 to 10 days) and milder manifestation of clinical symptoms (<a href="./references#CD002053-bbs2-0011" title="AlroomiLG , DavidsonJ , EvansTJ , GaleaP , HowatR . Maternal narcotic abuse and the newborn. Archives of Disease in Childhood1988;63(1):81-3. [DOI: 10.1136/adc.63.1.81] [PMID: 3348657]">Alroomi 1988</a>; <a href="./references#CD002053-bbs2-0051" title="BellGL , LauK . Perinatal and neonatal issues of substance abuse. Pediatric Clinics of North America1995;42(2):261-81. [DOI: 10.1016/s0031-3955(16)38946-5] [PMID: 7536914]">Bell 1995</a>; <a href="./references#CD002053-bbs2-0080" title="KocherlakotaP . Neonatal abstinence syndrome. Pediatrics2014;134(2):e547-61. [DOI: 10.1542/peds.2013-3524] [PMID: 25070299]">Kocherlakota 2014</a>; <a href="./references#CD002053-bbs2-0109" title="SiuA , RobinsonCA . Neonatal abstinence syndrome: essentials for the practitioner. Journal of Pediatric Pharmacology and Therapeutics2014;19(3):147-55. [DOI: 10.5863/1551-6776-19.3.147] [PMID: 25309144]">Siu 2014</a>). Conversely, withdrawal from methadone or buprenorphine has a usual onset of NAS from 48 hours to 72 hours with a more protracted (up to 30 days or more) and more pronounced manifestation of clinical symptoms (<a href="./references#CD002053-bbs2-0011" title="AlroomiLG , DavidsonJ , EvansTJ , GaleaP , HowatR . Maternal narcotic abuse and the newborn. Archives of Disease in Childhood1988;63(1):81-3. [DOI: 10.1136/adc.63.1.81] [PMID: 3348657]">Alroomi 1988</a>; <a href="./references#CD002053-bbs2-0053" title="BroglySB , SaiaKA , WalleyAY , DuHM , SebastianiP . Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. American Journal of Epidemiology2014;180(7):673-86. [DOI: 10.1093/aje/kwu190] [PMID: 25150272]">Brogly 2014</a>; <a href="./references#CD002053-bbs2-0056" title="CoyleMG , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , FisherG . Neonatal neurobehaviour effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. [DOI: 10.1111/j.1360-0443.2012.04040.x] [PMID: 23106928]">Coyle 2012</a>; <a href="./references#CD002053-bbs2-0018" title="DoberczakTM , KandallSR , WiletsI . Neonatal opiate abstinence syndrome in term and preterm infants. Journal of Pediatrics1991;118(6):933-7. [DOI: 10.1016/s0022-3476(05)82214-0] [PMID: 2040931]">Doberczak 1991</a>; <a href="./references#CD002053-bbs2-0061" title="FrickerHS , SegalS . Narcotic addiction, pregnancy, and the newborn. American Journal of Diseases of Children1978;132(4):360-6. [DOI: 10.1001/archpedi.1978.02120290032004] [PMID: 645651]">Fricker 1978</a>; <a href="./references#CD002053-bbs2-0071" title="JonesHE , KaltenbachK , HeilSH , StineMD , CoyleMD , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363(24):2320-31. [DOI: 10.1056/NEJMoa1005359] [PMID: 21142534]">Jones 2010</a>; <a href="./references#CD002053-bbs2-0080" title="KocherlakotaP . Neonatal abstinence syndrome. Pediatrics2014;134(2):e547-61. [DOI: 10.1542/peds.2013-3524] [PMID: 25070299]">Kocherlakota 2014</a>; <a href="./references#CD002053-bbs2-0083" title="LamSK , ToWK , DuthieSJ , MaHK . Narcotic addiction in pregnancy with adverse maternal and perinatal outcome. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1992;32(3):216-21. [DOI: 10.1111/j.1479-828x.1992.tb01950.x] [PMID: 1445130]">Lam 1992</a>; <a href="./references#CD002053-bbs2-0086" title="MaasU , KattnerE , Weingart-JesseB , SchaferA , ObladenM . Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. Journal of Perinatal Medicine1990;18(2):111-8. [DOI: 10.1515/jpme.1990.18.2.111] [PMID: 2366131]">Maas 1990</a>; <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002053-bbs2-0098" title="OlofssonM , BuckleyW , AndersenGE , Friis HansenBS . Investigation of 89 children born by drug-dependent mothers. I. Neonatal course. Acta Paediatrica Scandinavica1983;72:403-6. [DOI: 10.1111/j.1651-2227.1983.tb09736.x] [PMID: 6880727]">Olofsson 1983</a>; <a href="./references#CD002053-bbs2-0037" title="OstreaEM , ChavezCJ , StraussME . A study of factors that influence the severity of neonatal narcotic withdrawal. Addictive Diseases1975;2(1-2):187-99. [PMID: 1163362]">Ostrea 1975</a>). Although there is some evidence to correlate methadone dose and severity of withdrawal (<a href="./references#CD002053-bbs2-0057" title="DasheJS , SheffieldJS , OlscherDA , ToddSJ , JacksonGL , Wendel GD Jr. Relationship between maternal methadone dosage and neonatal withdrawal. Obstetrics and Gynecology2002;100(6):1244-9. [DOI: 10.1016/s0029-7844(02)02387-6] [PMID: 12468169]">Dashe 2002</a>; <a href="./references#CD002053-bbs2-0018" title="DoberczakTM , KandallSR , WiletsI . Neonatal opiate abstinence syndrome in term and preterm infants. Journal of Pediatrics1991;118(6):933-7. [DOI: 10.1016/s0022-3476(05)82214-0] [PMID: 2040931]">Doberczak 1991</a>; <a href="./references#CD002053-bbs2-0024" title="HarperRG , SolishG , FeingoldE , Gersten-WoolfNB , SokalMM . Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. American Journal of Obstetrics and Gynecology1977;129(4):417-24. [DOI: 10.1016/0002-9378(77)90588-9] [PMID: 910821]">Harper 1977</a>; <a href="./references#CD002053-bbs2-0037" title="OstreaEM , ChavezCJ , StraussME . A study of factors that influence the severity of neonatal narcotic withdrawal. Addictive Diseases1975;2(1-2):187-99. [PMID: 1163362]">Ostrea 1975</a>), and clinically significant manifestations of NAS are uncommon when the dose is below 20 mg/day (<a href="./references#CD002053-bbs2-0112" title="StraussME , AndreskoM , StrykerJC , WardellJN . Relationship of neonatal withdrawal to maternal methadone dose. American Journal of Drug and Alcohol Abuse1976;3(2):339-45. [DOI: 10.3109/00952997609077202] [PMID: 1032747]">Strauss 1976</a>), the association between methadone dosage in pregnancy and subsequent development of NAS is inconsistent (<a href="./references#CD002053-bbs2-0055" title="ClearyBJ , DonnellyJ , StrawbridgeJ , GallagherPJ , FaheyT , ClarkeM , et al. Methadone dose and neonatal abstinence syndrome – systematic review and meta-analysis. Addiction2010;105(12):2017-84. [DOI: 10.1111/j.1360-0443.2010.03120.x] [PMID: 20840198]">Cleary 2010</a>). There is some evidence that antenatal maintenance treatment with buprenorphine when compared to methadone may reduce the severity of NAS and length of hospital stay (<a href="./references#CD002053-bbs2-0053" title="BroglySB , SaiaKA , WalleyAY , DuHM , SebastianiP . Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. American Journal of Epidemiology2014;180(7):673-86. [DOI: 10.1093/aje/kwu190] [PMID: 25150272]">Brogly 2014</a>; <a href="./references#CD002053-bbs2-0056" title="CoyleMG , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , FisherG . Neonatal neurobehaviour effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. [DOI: 10.1111/j.1360-0443.2012.04040.x] [PMID: 23106928]">Coyle 2012</a>; <a href="./references#CD002053-bbs2-0071" title="JonesHE , KaltenbachK , HeilSH , StineMD , CoyleMD , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363(24):2320-31. [DOI: 10.1056/NEJMoa1005359] [PMID: 21142534]">Jones 2010</a>; <a href="./references#CD002053-bbs2-0073" title="KaltenbachK , HolbrookA , CoyleMG , HeilSH , SalisburyA , StineS , et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction2012;107(Suppl 1):45-52. [DOI: 10.1111/j.1360-0443.2012.04038.x] [23106926]">Kaltenbach 2012</a>). However, multiple‐drug use in pregnant women on maintenance buprenorphine has been reported to confound subsequent treatment of NAS in infants born to those women (<a href="./references#CD002053-bbs2-0102" title="PatelP , Abdel-LatifME , HazeltonB , WodakA , ChenJ , EmsleyF , et al. Perinatal outcomes of Australian buprenorphine-exposed mothers and their newborn infants. Journal of Paediatric and Child Health2013;49(9):746-53. [DOI: 10.1111/jpc.12264] [PMID: 23745982]">Patel 2013</a>). </p> <p>The clinical presentation of NAS may involve central nervous system (CNS) signs including tremors, irritability, increased wakefulness, high‐pitched crying, increased muscle tone, hyperactive deep tendon reflexes, exaggerated Moro reflex, seizures, frequent yawning and sneezing, poor feeding, unco‐ordinated and constant sucking; gastrointestinal signs including vomiting, diarrhoea, dehydration and poor weight gain; and autonomic signs including increased sweating, nasal stuffiness, fever, mottling and temperature instability (<a href="./references#CD002053-bbs2-0046" title="HudakML , TanRC , Committee on Drugs, Committee on Fetus and Newborn, American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics2012;129(2):e540-60. [DOI: 10.1542/peds.2011-3212] [PMID: 22291123]">AAP 2012</a>). Seizures occur in 2% to 11% of infants withdrawing from opioids (<a href="./references#CD002053-bbs2-0018" title="DoberczakTM , KandallSR , WiletsI . Neonatal opiate abstinence syndrome in term and preterm infants. Journal of Pediatrics1991;118(6):933-7. [DOI: 10.1016/s0022-3476(05)82214-0] [PMID: 2040931]">Doberczak 1991</a>; <a href="./references#CD002053-bbs2-0025" title="HerzlingerRA , KandallSR , Vaughan HG Jr. Neonatal seizures associated with narcotic withdrawal. Journal of Pediatrics1977;91(4):638-41. [DOI: 10.1016/s0022-3476(77)80523-4] [PMID: 908988]">Herzlinger 1977</a>; <a href="./references#CD002053-bbs2-0075" title="KandallSR , AlbinS , GartnerLM , LeeKS , EidelmanA , LowinsonJ . The narcotic-dependent mother: fetal and neonatal consequences. Early Human Development1977;1(2):159-69. [DOI: 10.1016/0378-3782(77)90017-2] [PMID: 617308]">Kandall 1977</a>), and may be more common with methadone than heroin withdrawal (<a href="./references#CD002053-bbs2-0025" title="HerzlingerRA , KandallSR , Vaughan HG Jr. Neonatal seizures associated with narcotic withdrawal. Journal of Pediatrics1977;91(4):638-41. [DOI: 10.1016/s0022-3476(77)80523-4] [PMID: 908988]">Herzlinger 1977</a>). However, benign myoclonus is also common in infants with NAS from opioids and associated with a normal electroencephalogram (EEG) (<a href="./references#CD002053-bbs2-0064" title="Held-EgliK , RueggerC , Das-KunduS , SchmittB , BucherHU . Benign neonatal sleep myoclonus in newborn infants of opioid dependent mothers. Acta Paediatrica2009;98(1):69-73. [DOI: 10.1111/j.1651-2227.2008.01010.x] [PMID: 18803624]">Held‐Egli 2009</a>). </p> <p>In human studies, exposure to in‐utero opioids has been reported to reduce fetal growth parameters and lower birth weights (<a href="./references#CD002053-bbs2-0060" title="FinneganLP , KandallSR . Maternal and neonatal effects of alcohol and drugs. In: LowinsonJH , RuizP , MillmanRB , LangrodJG , editors(s). Substance Abuse: a Comprehensive Textbook. Philadelphia (PA): Lippincott Williams &amp; Wilkins, 2005:805-39.">Finnegan 2005</a>; <a href="./references#CD002053-bbs2-0074" title="KandallSR , AlbinS , LowinsonJ , BerleB , EidelmanAI , GartnerLM . Differential effects of maternal heroin and methadone use on birthweight. Pediatrics1976;58(5):681-5. [PMID: 980601]">Kandall 1976</a>; <a href="./references#CD002053-bbs2-0078" title="KennareR , HeardA , ChanA . Substance abuse during pregnancy: risk factors and obstetric and perinatal outcomes in South Australia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005;45(3):220-5. [DOI: 10.1111/j.1479-828X.2005.00379.x] [PMID: 15904448]">Kennare 2005</a>); reduce neuroanatomic volumes (<a href="./references#CD002053-bbs2-0122" title="WalhovdKB , MoeV , SlinningK , Due-TønnessenP , BjørnerudA , DaleAM , et al. Volumetric cerebral characteristics of children exposed to opiates and other substances in utero. Neuroimage2007;36(4):1331-44. [DOI: 10.1016/j.neuroimage.2007.03.070] [PMID: 17513131]">Walhovd 2007</a>); alter neuronal connective tracts on imaging studies (<a href="./references#CD002053-bbs2-0123" title="WalhovdKB , WattsR , AmlienI , WoodwardLJ . Neural tract development of infants born to methadone-maintained mothers. Pediatric Neurology2012;47(1):1-6. [DOI: 10.1016/j.pediatrneurol.2012.04.008] [PMID: 22704008]">Walhovd 2012</a>); reduce newborn head circumference (<a href="./references#CD002053-bbs2-0119" title="ViscontiK , HennessyK , TowersC , HannessyM , HowardB . Opiate use in pregnancy and newborn head circumference. American Journal of Obstetrics and Gynecology2013;208:S67-8.">Visconti 2013</a>); and increase the risk of stillbirth (<a href="./references#CD002053-bbs2-0060" title="FinneganLP , KandallSR . Maternal and neonatal effects of alcohol and drugs. In: LowinsonJH , RuizP , MillmanRB , LangrodJG , editors(s). Substance Abuse: a Comprehensive Textbook. Philadelphia (PA): Lippincott Williams &amp; Wilkins, 2005:805-39.">Finnegan 2005</a>; <a href="./references#CD002053-bbs2-0078" title="KennareR , HeardA , ChanA . Substance abuse during pregnancy: risk factors and obstetric and perinatal outcomes in South Australia. Australian and New Zealand Journal of Obstetrics and Gynaecology2005;45(3):220-5. [DOI: 10.1111/j.1479-828X.2005.00379.x] [PMID: 15904448]">Kennare 2005</a>), neonatal mortality (<a href="./references#CD002053-bbs2-0068" title="HulseGK , MilneE , EnglishDR , HolmanCD . Assessing the relationship between maternal opiate use and neonatal mortality. Addiction1998;93(7):1033-42. [DOI: 10.1046/j.1360-0443.1998.93710338.x] [PMID: 9744134]">Hulse 1998</a>), and sudden infant death syndrome (<a href="./references#CD002053-bbs2-0076" title="KandallSR , GainesJ , HabelL , DavidsonG , JessopD . Relationship of maternal substance abuse to subsequent sudden infant death syndrome in offspring. Journal of Pediatrics1993;123(1):120-6. [DOI: 10.1016/s0022-3476(05)81554-9] [PMID: 8320605]">Kandall 1993</a>). In older children, failure to thrive and short stature (<a href="./references#CD002053-bbs2-0069" title="HuntRW , TzioumiD , CollinsE , JefferyHE . Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Human Development2008;84(1):29-35. [DOI: 10.1016/j.earlhumdev.2007.01.013] [PMID: 17728081]">Hunt 2008</a>), visual disturbances including refractive errors and nystagmus (<a href="./references#CD002053-bbs2-0110" title="Spiteri CornishK , HrabovskyM , ScottNW , MyerscoughE , ReddyAR . The short and long-term, effects on the visual system of children following exposure to maternal substance misuse in pregnancy. American Journal of Ophthalmology2013;156(1):190-4. [DOI: 10.1016/j.ajo.2013.02.004] [PMID: 23628351]">Spiteri Cornish 2013</a>), psychobehavioural problems such as impulsivity and attention‐deficit that may in turn lead to failure at school (<a href="./references#CD002053-bbs2-0097" title="OeiJL , MelhuishE , UebelH , AzzamN , BreenC , BurnsL , et al. Neonatal abstinence syndrome and high school performance. Pediatrics2017;139(2):e20162651. [DOI: 10.1542/peds.2016-2651] [PMID: 28093465]">Oei 2017</a>; <a href="./references#CD002053-bbs2-0113" title="Sundelin WahlstenV , SarmanI . Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy. Acta Paediatrics2013;102(5):544-9. [DOI: 10.1111/apa.12210] [PMID: 23432078]">Sundelin Wahlsten 2013</a>), have been associated with in‐utero exposure to opioids and other drugs. </p> </section> <section id="CD002053-sec-0011"> <h3 class="title" id="CD002053-sec-0011">Description of the intervention</h3> <p>Intervention begins with identification of infants with NAS. A variety of scoring systems identify and document the severity of clinical manifestations associated with NAS including the Lipsitz tool (<a href="./references#CD002053-bbs2-0085" title="LipsitzPJ . A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clinical Pediatrics1975;14(6):592-4. [DOI: 10.1177/000992287501400613] [PMID: 1126108]">Lipsitz 1975</a>), Neonatal Abstinence Scoring System (<a href="./references#CD002053-bbs2-0020" title="FinneganLP , Connaughton JF Jr, KronRE , EmichJP . Neonatal abstinence syndrome: assessment and management. Addictive Diseases1975;2(1-2):141-58. [PMID: 1163358]">Finnegan 1975a</a>), Neonatal Narcotic Withdrawal Index (<a href="./references#CD002053-bbs2-0063" title="GreenM , SuffetF . The neonatal narcotic withdrawal index: a device for the improvement of care in the abstinence syndrome. American Journal of Drug and Alcohol Abuse1981;8(2):203-13. [DOI: 10.3109/00952998108999125] [PMID: 7331976]">Green 1981</a>), Neonatal Withdrawal Inventory (<a href="./references#CD002053-bbs2-0126" title="ZahorodnyW , RomC , WhitneyW , GiddensS , SamuelM , MaichukG , et al. The neonatal withdrawal inventory: a simplified score of newborn withdrawal. Journal of Developmental and Behavioral Pediatrics1998;19:89-93. [DOI: 10.097/00004703-199804000-00005] [PMID: 9584937]">Zahorodny 1998</a>), and the MOTHER NAS Scale (<a href="./references#CD002053-bbs2-0072" title="JonesHE , SeashoreC , JohnsonE , HortonE , O'GradyKE , AndringaK , et al. Psychometric assessment of the neonatal abstinence scoring system and the MOTHER NAS Scale. American Journal of Addiction2016;25(5):370-3. [DOI: 10.1111/ajad.12388] [PMID: 27287965]">Jones 2016</a>). There are internal consistency, reliability and validity concerns with the use of scoring systems for NAS (<a href="./references#CD002053-bbs2-0049" title="BagleySM , WachmanEM , HollandE , BroglySB . Review of the assessment and management of neonatal abstinence syndrome. Addiction Science &amp; Clinical Practice2014;9(1):19. [DOI: 10.1186/1940-0640-9-19] [PMID: 25199822]">Bagley 2014</a>; <a href="./references#CD002053-bbs2-0072" title="JonesHE , SeashoreC , JohnsonE , HortonE , O'GradyKE , AndringaK , et al. Psychometric assessment of the neonatal abstinence scoring system and the MOTHER NAS Scale. American Journal of Addiction2016;25(5):370-3. [DOI: 10.1111/ajad.12388] [PMID: 27287965]">Jones 2016</a>; <a href="./references#CD002053-bbs2-0125" title="WolffK , Perez-MontejanoR . Opioid neonatal abstinence syndrome: controversies and implications for practice. Current Drug Abuse Reviews2014;7(1):454-8. [DOI: 10.2174/1874473707666141015215141] [PMID: 25323126]">Wolff 2014</a>), many of which relate to clinician competency in identifying symptoms of NAS and using the tool effectively (<a href="./references#CD002053-bbs2-0099" title="OrlandoS . An overview of clinical tools used to assess neonatal abstinence syndrome. Journal of Perinatal &amp; Neonatal Nursing2014;28(3):212-9. [DOI: 10.1097/JPN.0000000000000043] [PMID: 25062523]">Orlando 2014</a>), particularly where preterm infants are concerned (<a href="./references#CD002053-bbs2-0048" title="AlloccoE , MelkerM , Rojas-MiquezF , BradleyC , HahnKA , WachmanEM . Comparison of neonatal abstinence syndrome manifestations in preterm versus term opioid-exposed infants. Advances in Neonatal Care2016;16(5):329-36. [DOI: 10.1097/ANC.0000000000000320] [PMID: 27611018]">Allocco 2016</a>). Despite these inadequacies, the Neonatal Abstinence Scoring System (NASS) (<a href="./references#CD002053-bbs2-0020" title="FinneganLP , Connaughton JF Jr, KronRE , EmichJP . Neonatal abstinence syndrome: assessment and management. Addictive Diseases1975;2(1-2):141-58. [PMID: 1163358]">Finnegan 1975a</a>), or modified versions remains the most commonly used method for assessing withdrawal symptoms and determining treatment (<a href="./references#CD002053-bbs2-0081" title="KraftWK , van den Anker. Pharmacologic management of the opioid neonatal abstinence syndrome. Paediatric Clinics of North America2012;59(5):1147-65. [DOI: 10.1016/j.pcl.2012.07.006] [PMID: 23036249]">Kraft 2012</a>; <a href="./references#CD002053-bbs2-0082" title="KraftWK , StoverNW , DavisJM . Neonatal abstinence syndrome: pharmacologic strategies for the mother and infant. Seminars in Perinatology2016;40(3):203-12. [DOI: 10.1053/j.semperi.2015.12.007] [PMID: 26791055]">Kraft 2016</a>). In general, pharmacological interventions are commenced once an infant scores more than 8 on the Neonatal Abstinence Scoring System (<a href="./references#CD002053-bbs2-0082" title="KraftWK , StoverNW , DavisJM . Neonatal abstinence syndrome: pharmacologic strategies for the mother and infant. Seminars in Perinatology2016;40(3):203-12. [DOI: 10.1053/j.semperi.2015.12.007] [PMID: 26791055]">Kraft 2016</a>).Treatment for NAS typically involves a combination of pharmacological and non‐pharmacological interventions. Pharmacological interventions for NAS due to opioid withdrawal have included tincture of opium, paregoric, morphine, methadone and, more recently, buprenorphine. Sedatives used for opioid withdrawal have included clonidine, phenobarbital, diazepam and chlorpromazine (<a href="./references#CD002053-bbs2-0081" title="KraftWK , van den Anker. Pharmacologic management of the opioid neonatal abstinence syndrome. Paediatric Clinics of North America2012;59(5):1147-65. [DOI: 10.1016/j.pcl.2012.07.006] [PMID: 23036249]">Kraft 2012</a>; <a href="./references#CD002053-bbs2-0109" title="SiuA , RobinsonCA . Neonatal abstinence syndrome: essentials for the practitioner. Journal of Pediatric Pharmacology and Therapeutics2014;19(3):147-55. [DOI: 10.5863/1551-6776-19.3.147] [PMID: 25309144]">Siu 2014</a>; <a href="./references#CD002053-bbs2-0114" title="TheisJG , SelbyP , IkizlerY , KorenGS . Current management of the neonatal abstinence syndrome: a critical analysis of the evidence. Biology of the Neonate1997;71(6):345-56. [DOI: 10.1159/000244435] [PMID: 9197336]">Theis 1997</a>). Non‐pharmacological interventions have included reducing environmental stimuli, swaddling, settling, massage, relaxation baths, dummies (pacifiers) and waterbeds (<a href="./references#CD002053-bbs2-0049" title="BagleySM , WachmanEM , HollandE , BroglySB . Review of the assessment and management of neonatal abstinence syndrome. Addiction Science &amp; Clinical Practice2014;9(1):19. [DOI: 10.1186/1940-0640-9-19] [PMID: 25199822]">Bagley 2014</a>; <a href="./references#CD002053-bbs2-0100" title="OroAS , DixonSD . Waterbed care of narcotic-exposed neonates. A useful adjunct to supportive care. American Journal of Diseases of Children1988;142:186-8.">Oro 1988</a>). More recently, acupuncture (<a href="./references#CD002053-bbs2-0052" title="BoucherAM . Non-opioid management of neonatal abstinence syndrome. Advances in Neonatal Care2017;17(2):84-90. [DOI: 10.1097/ANC.0000000000000371] [PMID: 28002062]">Boucher 2017</a>; <a href="./references#CD002053-bbs2-0105" title="RaithW , SchmölzerBR , Fritz ReitererA . Laser acupuncture for neonatal abstinence syndrome: a randomised controlled trial. Pediatrics2015;136(5):876-84.">Raith 2015</a>), together with a much greater focus on promoting the mother–infant dyad through rooming‐in programmes (<a href="./references#CD002053-bbs2-0052" title="BoucherAM . Non-opioid management of neonatal abstinence syndrome. Advances in Neonatal Care2017;17(2):84-90. [DOI: 10.1097/ANC.0000000000000371] [PMID: 28002062]">Boucher 2017</a>; <a href="./references#CD002053-bbs2-0067" title="HowardMB , SchiffDM , PenwillN , RaiA , WolfgangT , MosesJM , et al. Impact of parental presence at infants' bedside on neonatal abstinence syndrome. Hospital Pediatrics2017;7(2):63-9. [DOI: 10.1542/hpeds.2016-0147] [PMID: 28137920]">Howard 2017</a>; <a href="./references#CD002053-bbs2-0093" title="NewmanA , DaviesGA , DowK , HolmesB , MacdonaldJ , McKnightS , et al. Rooming-in care for infants of opioid-dependent mothers. Canadian Family Physician2015;61(12):e555-61. [PMID: 27035006]">Newman 2015</a>) and breastfeeding (<a href="./references#CD002053-bbs2-0070" title="JanssonLM , SpencerN , McConnellK , VelezM , TutenM , HarrowCA , et al. Maternal buprenorphine maintenance and lactation. Journal of Human Lactation2016;32(4):675-81. [DOI: 10.1177/0890334416663198] [PMID: 27563013]">Jansson 2016</a>; <a href="./references#CD002053-bbs2-0108" title="ShortVL , GannonM , AbatemarcoDJ . The association between breastfeeding and length of hospital stay among infants diagnosed with neonatal abstinence syndrome: a population-based study on in-hospital births. Breastfeeding Medicine2016;11:343-9. [DOI: 10.1089/bfm.2016.0084] [PMID: 27529500]">Short 2016</a>), have been shown to reduce the need for pharmacological intervention, decrease the severity of NAS symptoms and reduce hospital length of stay. However, as two reviews have shown, there are no high‐quality clinical trials supporting efficacy of non‐pharmacological treatment interventions (<a href="./references#CD002053-bbs2-0087" title="MacMillanKD , RendonCP , VermaK , RibletN , WasherDB , HolmesAV . Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pediatrics2018;172(4):345-51. [DOI: 10.1001/jamapediatrics.2017.5195] [PMID: 29404599]">MacMillan 2018</a>; <a href="./references#CD002053-bbs2-0121" title="WachmanEM , SchiffDM , SilversteinM . Neonatal abstinence syndrome: advances in diagnosis and treatment. JAMA2018;319(13):1362-74. [DOI: 10.1001/jama.2018.2640] [PMID: 29614184]">Wachman 2018</a>). </p> </section> <section id="CD002053-sec-0012"> <h3 class="title" id="CD002053-sec-0012">How the intervention might work</h3> <p>Following delivery, the abrupt cessation of opioid supply to the newborn results in a cascade of neurotransmitter activity, which involves an increase in the production of noradrenaline, acetylcholine and corticotrophin, as well as a decrease in the production of serotonin and dopamine (<a href="./references#CD002053-bbs2-0080" title="KocherlakotaP . Neonatal abstinence syndrome. Pediatrics2014;134(2):e547-61. [DOI: 10.1542/peds.2013-3524] [PMID: 25070299]">Kocherlakota 2014</a>). Pharmacological interventions for NAS due to opioid withdrawal include opioid replacement therapies directed towards the μ‐opioid receptor. These include tincture of opium (contains ethanol 19%, and opium alkaloids including morphine and codeine), paregoric (contains ethanol 44%, anhydrous morphine, camphor, anise oil, benzoic acid, glycerine and antispasmodics (papaverine and noscapine)), morphine (natural opioid), methadone (a synthetic μ‐opioid receptor agonist) and more recently buprenorphine (a semi‐synthetic partial μ‐opioid receptor agonist and complete κ‐opioid receptor antagonist). Sedatives used for opioid withdrawal have included clonidine (an α2 adrenergic receptor agonist that ameliorates<br/>autonomic overactivity, such as tachycardia, hypertension, diaphoresis, restlessness and diarrhoea), phenobarbital and diazepam (gamma‐aminobutyric acid (GABA) receptor agonists that bind to different sites on the receptor, are sedative and reduce excitability) and chlorpromazine (a dopamine antagonist that may also reduce autonomic overactivity) (<a href="./references#CD002053-bbs2-0081" title="KraftWK , van den Anker. Pharmacologic management of the opioid neonatal abstinence syndrome. Paediatric Clinics of North America2012;59(5):1147-65. [DOI: 10.1016/j.pcl.2012.07.006] [PMID: 23036249]">Kraft 2012</a>; <a href="./references#CD002053-bbs2-0109" title="SiuA , RobinsonCA . Neonatal abstinence syndrome: essentials for the practitioner. Journal of Pediatric Pharmacology and Therapeutics2014;19(3):147-55. [DOI: 10.5863/1551-6776-19.3.147] [PMID: 25309144]">Siu 2014</a>; <a href="./references#CD002053-bbs2-0114" title="TheisJG , SelbyP , IkizlerY , KorenGS . Current management of the neonatal abstinence syndrome: a critical analysis of the evidence. Biology of the Neonate1997;71(6):345-56. [DOI: 10.1159/000244435] [PMID: 9197336]">Theis 1997</a>). </p> <p>The goals of therapy are to ensure that the infant achieves adequate sleep and nutrition to establish a consistent pattern of weight gain and begins to integrate into a social environment. The goal of pharmacological treatment is achievement of the desired therapeutic effect by using the least amount of drugs at the lowest doses and for the shortest durations possible (<a href="./references#CD002053-bbs2-0046" title="HudakML , TanRC , Committee on Drugs, Committee on Fetus and Newborn, American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics2012;129(2):e540-60. [DOI: 10.1542/peds.2011-3212] [PMID: 22291123]">AAP 2012</a>). Treatment is usually initiated and titrated to NAS withdrawal scores. Once stabilised, treatment is withdrawn while continuing to monitor NAS withdrawal scores. In infants with predominant opioid dependency, opioid replacement therapy is usually titrated down gradually, whereas sedatives prescribed for relatively short periods can be titrated more rapidly allowing for shorter durations of treatment and earlier discharge of infants from hospital. However, although it is common for infants receiving pharmacological treatment for NAS to remain in hospital, there are increasing reports of safe discharge of infants receiving treatment (<a href="./references#CD002053-bbs2-0077" title="KellyLE , KnoppertD , RoukemaH , RiederMJ , KorenG . Oral morphine weaning for neonatal abstinence syndrome at home compared with in-hospital: an observational cohort study. Paediatric Drugs2015;17(2):151-7. [10.1007/s40272-014-0096-y] [PMID: 25342143]">Kelly 2015</a>; <a href="./references#CD002053-bbs2-0090" title="MiddletonM , WrightI , OeiJL , TravadiJ . Management of infants with neonatal abstinence syndrome in a tertiary care hospital. Journal of Paediatrics and Child Health2017;53(Suppl 2):106.">Middleton 2017</a>). </p> </section> <section id="CD002053-sec-0013"> <h3 class="title" id="CD002053-sec-0013">Why it is important to do this review</h3> <p>Recommended first‐line pharmacological treatment for newborns experiencing NAS from opioid withdrawal is generally with an opioid and may include adjunctive treatment with a sedative (<a href="./references#CD002053-bbs2-0046" title="HudakML , TanRC , Committee on Drugs, Committee on Fetus and Newborn, American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics2012;129(2):e540-60. [DOI: 10.1542/peds.2011-3212] [PMID: 22291123]">AAP 2012</a>). For sedative‐hypnotic withdrawal, phenobarbital is recommended (<a href="./references#CD002053-bbs2-0046" title="HudakML , TanRC , Committee on Drugs, Committee on Fetus and Newborn, American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics2012;129(2):e540-60. [DOI: 10.1542/peds.2011-3212] [PMID: 22291123]">AAP 2012</a>). It may be that, by using a sedative, many infants will avoid further opioid exposure and duration of treatment will be reduced to the period of acute withdrawal. Non‐pharmacological treatments directed at rooming‐in, skin‐to‐skin and breastfeeding are also advantageous (<a href="./references#CD002053-bbs2-0087" title="MacMillanKD , RendonCP , VermaK , RibletN , WasherDB , HolmesAV . Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pediatrics2018;172(4):345-51. [DOI: 10.1001/jamapediatrics.2017.5195] [PMID: 29404599]">MacMillan 2018</a>; <a href="./references#CD002053-bbs2-0121" title="WachmanEM , SchiffDM , SilversteinM . Neonatal abstinence syndrome: advances in diagnosis and treatment. JAMA2018;319(13):1362-74. [DOI: 10.1001/jama.2018.2640] [PMID: 29614184]">Wachman 2018</a>), and may be challenging for clinicians to facilitate. The questions to be addressed by this review are: </p> <p> <ol id="CD002053-list-0001"> <li> <p>what is the evidence, from randomised controlled trials (RCTs) and quasi‐RCTs, that a sedative is better than control in the treatment of clinically significant NAS due to opioid withdrawal (control may be placebo, the usual management of the newborn infant or any form of non‐pharmacological treatment designed to settle the infant and mother, establish feeding and facilitate mother–infant interactions)? and </p> </li> <li> <p>what is the evidence for use of a specific sedative from trials comparing different types of sedatives? </p> </li> </ol> </p> <p>The goal of treatment should be to provide comfort to the mother and infant in relieving symptoms; improve feeding and weight gain, prevent seizures, reduce unnecessary hospitalisation in the infant; improve mother–infant interaction and reduce the incidence of infant mortality and abnormal neurodevelopment. This is an update of a previous review (<a href="./references#CD002053-bbs2-0129" title="OsbornDA , JefferyHE , ColeMJ . Sedatives for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD002053. [DOI: 10.1002/14651858.CD002053]">Osborn 2002</a>; <a href="./references#CD002053-bbs2-0130" title="OsbornDA , JefferyHE , ColeMJ . Sedatives for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD002053. [DOI: 10.1002/14651858.CD002053.pub2]">Osborn 2005</a>; <a href="./references#CD002053-bbs2-0131" title="OsbornDA , JefferyHE , ColeMJ . Sedatives for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2010, Issue 10. Art. No: CD002053. [DOI: 10.1002/14651858.CD002053.pub3]">Osborn 2010</a>). A separate review, examines the evidence for the use of opioids in infants with NAS due to opioid withdrawal (<a href="./references#CD002053-bbs2-0127" title="ZanklA , MartinJ , DaveyJG , OsbornDA . Opioid treatment for opioid withdrawal in newborn infants. Cochrane Database of Systematic Reviews (in press).">Zankl 2021</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002053-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002053-sec-0014"></div> <p>To assess the effectiveness and safety of using a sedative versus control (placebo, usual treatment or non‐pharmacological treatment) for NAS due to withdrawal from opioids and determine which type of sedative is most effective and safe for NAS due to withdrawal from opioids. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002053-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002053-sec-0015"></div> <section id="CD002053-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002053-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered all published and unpublished trials using random or quasi‐random patient allocation. Cluster randomised trials where the unit of randomisation was a group of participants were eligible. We excluded cross‐over trials. </p> </section> <section id="CD002053-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included infants in the neonatal period with NAS born to mothers with an opioid dependence. Withdrawal may have been determined by the presence of signs consistent with NAS or the use of a standardised score of NAS. </p> </section> <section id="CD002053-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Trials comparing the following were eligible.</p> <p> <ol id="CD002053-list-0002"> <li> <p><b>Sedative versus placebo or no treatment/usual care:</b> </p> <ol id="CD002053-list-0003"> <li> <p>phenobarbital versus placebo or no treatment/usual care;</p> </li> <li> <p>diazepam versus placebo or no treatment/usual care;</p> </li> <li> <p>chlorpromazine versus placebo or no treatment/usual care; or</p> </li> <li> <p>clonidine versus placebo or no treatment/usual care.</p> </li> </ol> </li> <li> <p><b>Sedative versus other sedative</b> – <b>specific comparisons:</b> </p> <ol id="CD002053-list-0004"> <li> <p>phenobarbital versus diazepam;</p> </li> <li> <p>phenobarbital versus chlorpromazine;</p> </li> <li> <p>phenobarbital versus clonidine;</p> </li> <li> <p>diazepam versus chlorpromazine;</p> </li> <li> <p>diazepam versus clonidine or</p> </li> <li> <p>chlorpromazine versus clonidine.</p> </li> </ol> </li> <li> <p><b>Sedative versus sedative in opioid treated infants:</b> </p> <ol id="CD002053-list-0005"> <li> <p>including any of the comparisons documented above in 2.</p> </li> </ol> </li> <li> <p><b>Addition of a sedative in opioid treated infants.</b> </p> </li> <li> <p><b>Addition of an opioid versus other sedative in sedative treated infants:</b> </p> <ol id="CD002053-list-0006"> <li> <p>including any of the comparisons documented above in 2.</p> </li> </ol> </li> </ol> </p> </section> <section id="CD002053-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Outcomes are reported to discharge or latest time reported as appropriate.</p> <section id="CD002053-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD002053-list-0007"> <li> <p>Treatment failure: including failure to achieve control defined as a failure to reduce a standardised score of NAS from a clinically significant level to a clinically 'safe' level defined by author of trial, or the use of additional pharmacological treatments for control of NAS in the neonatal period. </p> </li> <li> <p>Seizures (paroxysmal alterations in neurological function. This could have been behavioural, motor or autonomic (<a href="./references#CD002053-bbs2-0120" title="VolpeJJ . Neonatal seizures. In: Neurology of the Newborn. Philadelphia (PA): Saunders Elsevier, 2008:203-44. [ISBN: 9781416039952]">Volpe 2008</a>). Neonatal seizures could have been clinical (with no EEG correlate), electroclinical (clinical associated with EEG findings) or electrographic (no clinical correlate) (<a href="./references#CD002053-bbs2-0091" title="MizrahiEM , KellawayP . Characterization and classification of neonatal seizures. Neurology1987;37(12):1837-44. [DOI: 10.1212/wnl.37.12.1837] [PMID: 3683874]">Mizrahi 1987</a>).) </p> </li> <li> <p>Neonatal (latest time reported to discharge) and infant mortality.</p> </li> <li> <p>Neurodevelopmental disability at 18 months' postnatal age or greater defined as a neurological abnormality including any one of the following: </p> <ol id="CD002053-list-0008"> <li> <p>cerebral palsy on clinical examination;</p> </li> <li> <p>developmental delay more than two standard deviations (SDs) below population mean on a standardised test of development; </p> </li> <li> <p>blindness (visual acuity less than 6/60) or</p> </li> <li> <p>deafness (any hearing impairment requiring amplification) at any time after term corrected.</p> </li> </ol> </li> </ol> </p> </section> <section id="CD002053-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD002053-list-0009"> <li> <p>Time to control of NAS (control of symptoms or reduction of NAS score to a clinically 'safe' level). </p> </li> <li> <p>Days' admission to a newborn nursery.</p> </li> <li> <p>Days' hospitalisation.</p> </li> <li> <p>Days' pharmacological treatment of NAS.</p> </li> <li> <p>Days to establishment of full sucking feeds.</p> </li> <li> <p>Success of breastfeeding (exclusive breastfeeding; partial breastfeeding – at discharge; one, four and six months). </p> </li> <li> <p>Postnatal growth failure (weight less than 10th percentile at discharge).</p> </li> <li> <p>Infant growth: up to age one month; at latest time measured (definition = from one month to time of discharge); to follow‐up beyond 12 months: </p> <ol id="CD002053-list-0010"> <li> <p>weight gain (grams per kilogram per day);</p> </li> <li> <p>linear growth (centimetres per week);</p> </li> <li> <p>head circumference (centimetres per week).</p> </li> </ol> </li> <li> <p>Change of standardised growth: up to age one month; at latest time measured (definition = from one month to time of discharge); to follow‐up beyond 12 months: </p> <ol id="CD002053-list-0011"> <li> <p>change in weight z‐score;</p> </li> <li> <p>change in length z‐score;</p> </li> <li> <p>change in head circumference z‐score.</p> </li> </ol> </li> <li> <p>Adverse effects occurring after commencement of therapy:</p> <ol id="CD002053-list-0012"> <li> <p>apnoea;</p> </li> <li> <p>need for resuscitation;</p> </li> <li> <p>need for mechanical ventilation.</p> </li> </ol> </li> <li> <p>Disruption to the mother–infant relationship (e.g. separation of mother and infant, admission to a newborn nursery, failure to successfully breastfeed, maternal depression or parental dissatisfaction). </p> </li> <li> <p>Out‐of‐home care (foster care; adoption).</p> </li> </ol> </p> </section> </section> </section> <section id="CD002053-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002053-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We conducted a comprehensive updated search in September 2020, including: Cochrane Central Register of Controlled Trials (CENTRAL 2020, Issue 9) in the Cochrane Library, and Ovid MEDLINE(R) and Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Daily and Versions(R) (2010 to 17 September 2020). We included the search strategies for each database in <a href="./appendices#CD002053-sec-0127">Appendix 1</a>. We applied no language restrictions. </p> <p>We searched clinical trial registries for ongoing or recently completed trials. We searched the WHO's International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>), and the U.S. National Library of Medicine's ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>), via Cochrane CENTRAL. Additionally, we searched the ISRCTN Registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>), for any unique trials not found through the Cochrane CENTRAL search. </p> <p>We used Cochrane's Screen4Me workflow to help assess the search results. Screen4Me comprises three components: known assessments – a service that matches records in the search results to records that have already been screened in Cochrane Crowd and been labelled as a <i>RCT</i> or as <i>Not an RCT</i>; and the RCT classifier – a machine learning model that distinguishes RCTs from non‐RCTs. </p> <p>For more information about Screen4Me and the evaluations that have been performed, see the Screen4Me webpage on the Cochrane Information Specialist's portal: <a href="https://community.cochrane.org/organizational-info/resources/resources-groups/information-specialists-portal/crs-videos-and-quick-reference-guides#Screen4Me" target="_blank">community.cochrane.org/organizational-info/resources/resources-groups/information-specialists-portal/crs-videos-and-quick-reference-guides#Screen4Me</a>. In addition, there is more detailed information regarding evaluations of the Screen4Me components in the following publications: <a href="./references#CD002053-bbs2-0088" title="MarshallIJ , Noel-StorrAH , KuiperJ , ThomasJ , WallaceBC . Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide. Research Synthesis Methods2018;9(4):1-12. [DOI: 10.1002/jrsm.1287] [PMID: 29314757]">Marshall 2018</a>; <a href="./references#CD002053-bbs2-0089" title="McDonaldS , Noel-StorrAH , ThomasJ . Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane Reviews. Abstracts of the Global Evidence Summit, Cape Town, South Africa. Cochrane Database of Systematic Reviews2017;9(Suppl 1). [DOI: doi.org/10.1002/14651858.CD201702]">McDonald 2017</a>; <a href="./references#CD002053-bbs2-0096" title="Noel-Storr AH and the Project Transform team. Cochrane Crowd and Classmate: new ways of working and learning together to produce health evidence. Abstracts of the 26th Cochrane Colloquium, Santiago, Chile. Cochrane Database of Systematic Reviews2020;1(Suppl 1). [DOI: doi.org/10.1002/14651858.CD201901]">Noel‐Storr 2018</a>; <a href="./references#CD002053-bbs2-0115" title="ThomasJ , Noel-StorrAH , MarshallI , WallaceB , McDonaldS , MavergamesC , et al, Living Systematic Review Network. Living systematic reviews: 2. Combining human and machine effort. Journal of Clinical Epidemiology2017;91:31-7. [DOI: 10.1016/j.jclinepi.2017.08.011] [PMID: 28912003]">Thomas 2017</a>. </p> <p>This is the third update of this review. Our previous search details are listed in <a href="./appendices#CD002053-sec-0131">Appendix 2</a>. </p> </section> <section id="CD002053-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We included in our search strategy searches of citations of included studies for references to other trials; previous reviews including cross‐references; abstracts and conferences and symposia proceedings of Pediatric Academic Societies (American Pediatric Society, Society for Pediatric Research and European Society of Paediatric Research to 2019) and Perinatal Society of Australia and New Zealand from 2010 to 2019. We attempted to contact the corresponding investigator for information if we identified any unpublished trials. We considered unpublished studies or studies only reported as abstracts as eligible for inclusion in the review if methods and data could be confirmed by the study author. </p> </section> </section> <section id="CD002053-sec-0026"> <h3 class="title" id="CD002053-sec-0026">Data collection and analysis</h3> <p>We used the standard methods of Cochrane as documented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002053-bbs2-0066" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>), and recommended by Cochrane Neonatal. </p> <section id="CD002053-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Three review authors (AZ, JM, DO) independently assessed all potential studies identified as a result of the search strategy for inclusion. We resolved any differences of opinion through discussion. </p> </section> <section id="CD002053-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>For the 2021 review update, three review authors (AZ, JM, DO) independently extracted data using a specifically designed data extraction sheet to manage information. We resolved any differences in opinion through discussion with data then entered into Review Manager 5 (<a href="./references#CD002053-bbs2-0106" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>), and cross‐checked for accuracy. One review author (DO) extracted data and requested additional data from the authors of three trials (<a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a>), for the 2010 review update (<a href="./references#CD002053-bbs2-0131" title="OsbornDA , JefferyHE , ColeMJ . Sedatives for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2010, Issue 10. Art. No: CD002053. [DOI: 10.1002/14651858.CD002053.pub3]">Osborn 2010</a>), which remains current for this review. Two review authors (DO and HJ) extracted data independently then compared data and resolved differences for the 2005 update (<a href="./references#CD002053-bbs2-0130" title="OsbornDA , JefferyHE , ColeMJ . Sedatives for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2005, Issue 3. Art. No: CD002053. [DOI: 10.1002/14651858.CD002053.pub2]">Osborn 2005</a>), and 2002 review (<a href="./references#CD002053-bbs2-0129" title="OsbornDA , JefferyHE , ColeMJ . Sedatives for opiate withdrawal in newborn infants. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD002053. [DOI: 10.1002/14651858.CD002053]">Osborn 2002</a>). </p> </section> <section id="CD002053-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (AZ, JM, DO) independently assessed the risk of bias (low, high or unclear) of all included trials using the Cochrane 'Risk of bias' tool for the following domains (<a href="./references#CD002053-bbs2-0065" title="HigginsJP , AltmanDG , SterneJA , on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>): </p> <p> <ol id="CD002053-list-0013"> <li> <p>sequence generation (selection bias);</p> </li> <li> <p>allocation concealment (selection bias);</p> </li> <li> <p>blinding of participants and personnel (performance bias);</p> </li> <li> <p>blinding of outcome assessment (detection bias);</p> </li> <li> <p>incomplete outcome data (attrition bias);</p> </li> <li> <p>selective reporting (reporting bias);</p> </li> <li> <p>any other bias.</p> </li> </ol> </p> <p>We resolved any disagreements by discussion. See <a href="./appendices#CD002053-sec-0132">Appendix 3</a> for a more detailed description of risk of bias for each domain. </p> </section> <section id="CD002053-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We conducted statistical analyses using the statistical package in Review Manager 5 (<a href="./references#CD002053-bbs2-0106" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We summarised the data in a meta‐analysis if they were sufficiently homogeneous, both clinically and statistically. </p> <section id="CD002053-sec-0031"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we presented results using risk ratios (RR) and risk differences (RD) with 95% confidence intervals (CIs). We will calculate the number needed to treat for an additional beneficial outcome (NNTB), or an additional harmful outcome (NNTH) with 95% CIs if there is a statistically significant change in RD. </p> </section> <section id="CD002053-sec-0032"> <h5 class="title">Continuous data</h5> <p>For continuous data, we used the mean difference (MD) when outcomes were measured in the same way between trials. We used the standardised mean difference (SMD) to combine trials that measured the same outcome but used different methods. Where trials reported continuous data as median and interquartile range (IQR) and data passed the test of skewness, we converted mean to median and estimated the SD as IQR/1.35. </p> </section> </section> <section id="CD002053-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of randomisation was the intended unit of analysis. Cluster‐RCTs were eligible.</p> <section id="CD002053-sec-0034"> <h5 class="title">Cluster‐randomised trials</h5> <p>We intended to analyse cluster‐randomised trials in the analyses along with individually randomised trials. We intended to analyse them using the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002053-bbs2-0066" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>), using an estimate of the intracluster correlation coefficient (ICC) derived from the trial (if possible) or from another source. If ICCs from other sources were used, this was reported and a sensitivity analysis conducted to investigate the effect of variations in the ICC. Where cluster‐randomised trials and individually randomised trials were identified, we synthesised relevant information. We considered it reasonable to combine the results from both if there was little heterogeneity between study designs, and if interaction between effect of the intervention and choice of randomisation unit unlikely. </p> </section> </section> <section id="CD002053-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We obtained missing data from the study authors when possible. Where missing data could not be obtained, we examined the effect of excluding trials with substantial missing data (e.g. greater than 10% losses) in sensitivity analyses. </p> <p>We attempted to overcome potential bias from missing data (greater than 10% losses) using one or more of the following approaches: </p> <p> <ol id="CD002053-list-0014"> <li> <p>whenever possible, contacting the original investigators to request missing data;</p> </li> <li> <p>performing sensitivity analyses to assess how sensitive the results were to reasonable changes in the assumptions that were made (e.g. the effect of excluding trials with substantial missing data (greater than 10% losses)); </p> </li> <li> <p>addressing the potential impact of missing data (greater than 10% losses) upon the findings of the review in the 'Discussion' section. </p> </li> </ol> </p> </section> <section id="CD002053-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used Review Manager 5 to assess the heterogeneity of treatment effects between trials (<a href="./references#CD002053-bbs2-0106" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>), using the two statistical methods described below. </p> <p> <ol id="CD002053-list-0015"> <li> <p>The Chi² test, to assess whether observed variability in effect sizes between studies was greater than would be expected by chance. Since this test has low power when the number of studies included in the meta‐analysis was small, we planned to set the probability at the 10% level of significance. </p> </li> <li> <p>The I² statistic to ensure that pooling of data was valid. We considered a degree of heterogeneity less than 25% to represent no heterogeneity, 25% to 49% to represent minimal heterogeneity, 50% to 74% to represent moderate heterogeneity and 75% or greater to represent substantial or high heterogeneity. </p> </li> </ol> </p> <p>We assessed the source of heterogeneity using sensitivity and subgroup analysis, looking for evidence of bias or methodological differences between trials where there was evidence of apparent or statistical heterogeneity. </p> </section> <section id="CD002053-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias by comparing the stated primary outcomes and secondary outcomes and reported outcomes of each study. Where study protocols were available, we compared these to the full publications to determine the likelihood of reporting bias. We documented studies using the interventions in a potentially eligible infant population but not reporting on any of the primary and secondary outcomes in the <a href="./references#CD002053-sec-0149" title="">Characteristics of included studies</a> table. We used the funnel plots to screen for publication bias where there were sufficient numbers of studies (more than 10) reporting the same outcome. If publication bias was suggested by a significant asymmetry of the funnel plot on visual assessment, we planned to incorporate this in our assessment of the certainty of the evidence. </p> </section> <section id="CD002053-sec-0038"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using Review Manager 5 (<a href="./references#CD002053-bbs2-0106" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We used the fixed‐effect model Mantel‐Haenszel meta‐analysis for dichotomous outcomes and fixed‐effect model inverse variance meta‐analysis for combining data where trials examined the same intervention and the populations and methods of the trials were similar. We intended to assess the possible source(s) of heterogeneity using subgroup and sensitivity analysis. </p> </section> <section id="CD002053-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Planned subgroup analyses included the following identified subcategories:</p> <p> <ol id="CD002053-list-0016"> <li> <p>according to type of sedative used (e.g. clonidine, a benzodiazepine, barbiturate or neuroleptic agent); </p> </li> <li> <p>according to type of non‐pharmacological treatment used;</p> </li> <li> <p>according to whether trials included mothers with only opioid dependence or with multiple drug use; </p> </li> <li> <p>according to age of the infants at treatment (e.g. early versus delayed treatment) and duration of treatment (e.g. short versus long course). </p> </li> </ol> </p> <p>All outcomes were eligible for inclusion in subgroup analysis.</p> </section> <section id="CD002053-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to undertake sensitivity analyses on the basis of methodological quality. Trials of good methodology had adequate randomisation and allocation concealment, blinding of treatment and greater than 90% follow‐up on an intention‐to‐treat basis. </p> </section> <section id="CD002053-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach, as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE Handbook</a> (<a href="./references#CD002053-bbs2-0107" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>), to assess the certainty of evidence for the following (clinically relevant) outcomes: </p> <p> <ol id="CD002053-list-0017"> <li> <p>treatment failure;</p> </li> <li> <p>seizures;</p> </li> <li> <p>neonatal and infant mortality;</p> </li> <li> <p>neurodevelopmental disability;</p> </li> <li> <p>days' hospitalisation;</p> </li> <li> <p>days' pharmacological treatment of NAS;</p> </li> <li> <p>adverse events.</p> </li> </ol> </p> <p>Three review authors (AZ, JM, DO) independently assessed the certainty of the evidence for each of the outcomes above. We considered evidence from RCTs as high certainty but downgraded by one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates and presence of publication bias. We used the <a href="./references#CD002053-bbs2-0062" title="GRADEpro GDT. Version accessed 20 April 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2017. Available at gradepro.org.">GRADEpro GDT</a> Guideline Development Tool to create six 'Summary of findings' tables to report the certainty of the evidence for each comparison. </p> <p>The GRADE approach results in an assessment of the certainty of a body of evidence as one of four grades. </p> <p> <ol id="CD002053-list-0018"> <li> <p>High certainty: further research is very unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>Very low certainty: we are very uncertain about the estimate.</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002053-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002053-sec-0042"></div> <section id="CD002053-sec-0043"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD002053-sec-0149" title="">Characteristics of included studies</a>; <a href="./references#CD002053-sec-0150" title="">Characteristics of excluded studies</a>; and <a href="./references#CD002053-sec-0151" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD002053-sec-0044"> <h4 class="title">Results of the search</h4> <p>The search was updated in September 2020 (<a href="#CD002053-fig-0001">Figure 1</a>; <a href="#CD002053-fig-0002">Figure 2</a>). We excluded 34 studies (34 reports) (see <a href="./references#CD002053-sec-0150" title="">Characteristics of excluded studies</a> table). Ten studies (21 reports) were eligible for inclusion (see <a href="./references#CD002053-sec-0149" title="">Characteristics of included studies</a> table). One study of clonidine as adjunct to morphine is ongoing (see <a href="./references#CD002053-sec-0151" title="">Characteristics of ongoing studies</a> table). </p> <div class="figure" id="CD002053-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Screen4Me summary diagram. RCT: randomised controlled trial." data-id="CD002053-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Screen4Me summary diagram. RCT: randomised controlled trial.</p> </div> </div> </div> <div class="figure" id="CD002053-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram: review update" data-id="CD002053-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: review update</p> </div> </div> </div> </section> <section id="CD002053-sec-0045"> <h4 class="title">Included studies</h4> <p>We assessed 10 studies as eligible for inclusion (<a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>; <a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a>; <a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a>; <a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a>; <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a>; <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>; <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). Two studies may be sequential reports in which some of the participants were the same (author communication) (<a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>). In view of this uncertainty, outcomes that are reported by <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a> that were previously reported by <a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a> were not included in the meta‐analyses tables, but were reported separately in the text (see <a href="./full#CD002053-sec-0042">Results</a>). </p> <section id="CD002053-sec-0046"> <h5 class="title">Participants</h5> <p>One study was conducted in Australia (<a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a>), one in Switzerland (<a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>), and the remainder in the USA. The 10 studies enrolled 581 infants. All studies enrolled infants experiencing NAS born to mothers using opioids and other drugs. One study reported infants of mothers using only opioids separately (<a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>). One study excluded those infants born to mothers who disclosed using benzodiazepines (<a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>). Eight studies used the Neonatal Abstinence Scoring System (NASS) or a modification thereof with treatment generally commenced when the mean of three consecutive scores was 8 or greater or a single score was 12 or greater (<a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>; <a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a>; <a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a>; <a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a>; <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>; <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). Two studies had modifications of criteria. <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a> commenced treatment when two consecutive modified NASS scores were 8 or greater, and <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> when two consecutive scores were greater than 9 or once scored greater than 14. <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a> used a scoring system based on a grading system for tremors and irritability. <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> reported using clinical decision to treat and did not use a scoring system. </p> </section> <section id="CD002053-sec-0047"> <h5 class="title">Interventions</h5> <p>Six studies titrated the dosage of treatment interventions in both arms according to a nominated institutional NAS scoring system (<a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a>; <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a>; <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>; <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>), or 'clinical assessment' for one study (<a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). <a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a> titrated the dose of dilute tincture of opium (DTO) in both groups to the modified NASS score and compared the addition of a fixed dose of clonidine versus placebo. <a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a> compared clonidine titrated to the NASS score versus phenobarbital adjusted to obtain a serum trough concentration of 25 µg/mL to 30 µg/mL. <a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a> compared phenobarbital adjusted to obtain a serum trough level 20 µg/mL to 30 µg/mL to placebo. Five studies did not report adjunctive treatments used when allocated first treatment drug failed to control NAS (<a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>; <a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a>; <a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a>; <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). Five studies used the alternative primary study treatment when allocated treatment failed (<a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a>; <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a>; <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>; <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). </p> <section id="CD002053-sec-0048"> <h6 class="title">Sedative versus placebo or no treatment/usual care</h6> <section id="CD002053-sec-0049"> <p><b>Phenobarbital versus supportive care</b></p> <p><a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a> compared phenobarbital 15 mg/kg (intramuscular loading dose) then 6 mg/kg/day orally in two divided doses, titrated to score up to maximum 10 mg/kg/day versus supportive care only. </p> </section> </section> <section id="CD002053-sec-0050"> <h6 class="title">Sedative versus other sedative</h6> <section id="CD002053-sec-0051"> <p><b>Phenobarbital versus diazepam</b></p> <p><a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a> compared phenobarbital with or without a loading dose of 20 mg/kg with maintenance 5 mg/kg/day to 10 mg/kg/day titrated against score, until control of NAS was obtained or serum concentration greater than 70 μg/mL or evidence of toxicity, versus diazepam (dose not reported). </p> <p><a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a> compared phenobarbital loading dose followed by maintenance titrated to score versus phenobarbital maintenance only (doses not reported but likely to be same at reported by <a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>) versus diazepam (dose not reported). </p> <p><a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> compared phenobarbital 5 mg/kg/day to 8 mg/kg/day (three divided doses) versus diazepam 0.5 mg to 2.0 mg eight hourly with doses "tailored day to day". </p> </section> <section id="CD002053-sec-0052"> <p><b>Phenobarbital versus chlorpromazine</b></p> <p><a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a> compared phenobarbital short course 8.4 mg/kg/day (four divided doses) for four days then stopped versus phenobarbital long course 8.4 mg/kg/day (four divided doses) for 10 days then reduced by one third every second day and stopped day 16 versus chlorpromazine short course 2.8 mg/kg/day (four divided doses) for four days then stopped versus chlorpromazine long course 2.8 mg/kg/day (four divided doses) for 10 days then gradual reduction over next six days. </p> <p><a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> compared chlorpromazine starting dose 0.5 mg/kg four hourly to maximal 1 mg/kg four hourly (3 mg/kg/day to 6 mg/kg/day) versus phenobarbital loading dose 10 mg/kg then maintenance 0.83 mg/kg four hourly to maximum 1.66 mg/kg four hourly (5 mg/kg/day to 10 mg/kg/day), both titrations occurred if the NASS score was greater than 9. </p> </section> <section id="CD002053-sec-0053"> <p><b>Phenobarbital titration with loading dose versus phenobarbitone titration alone</b></p> <p><a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a> compared phenobarbital loading dose followed by maintenance titrated to score versus phenobarbital maintenance only (doses not reported). </p> </section> </section> <section id="CD002053-sec-0054"> <h6 class="title">Sedative versus sedative in opioid‐treated infants</h6> <section id="CD002053-sec-0055"> <p><b>Clonidine and morphine versus phenobarbital and morphine</b></p> <p><a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a>, in infants who failed morphine therapy (morphine dose greater than 0.16 mg every three hours or failed two weaning attempts), compared clonidine 6 μg/kg/day divided every three hours titrated to score in increments of 1.5 μg/kg/day every 24 hours up to maximum 12 μg/kg/day versus phenobarbital 20 mg/kg loading dose divided 12 hourly, then 2.5 mg/kg 12 hourly adjusted to obtain a trough 25 to 30 μg/mL. </p> <p><a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>, in infants treated with morphine 0.32 mg/kg/day to a maximum 0.8 mg/kg/day titrated to scores, compared clonidine 6 μg/kg/day to a maximum 12 μg/kg/day according to score, given every six hours in divided daily dose, versus phenobarbital 6 mg/kg/day to a maximum 12 mg/kg/day given every eight hours in divided daily dose titrated according to score. </p> </section> </section> <section id="CD002053-sec-0056"> <h6 class="title">Addition of a sedative in opioid‐treated infants</h6> <section id="CD002053-sec-0057"> <p><b>DTO and clonidine versus DTO and placebo</b></p> <p><a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>, in infants treated with DTO 0.48 mg/day titrated to maximum 2.88 mg/day, compared oral clonidine 1 μg/kg every four hours (6 μg/kg/day) versus placebo (no titration). </p> </section> <section id="CD002053-sec-0058"> <p><b>DTO and phenobarbitone versus DTO and placebo</b></p> <p><a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a>, in infants treated with DTO (morphine 0.4 mg/mL) 0.12 mg/kg/day to 0.16 mg/kg/day, compared phenobarbital loading dose 30 mg/kg (given as three oral doses every 12 hours) and maintenance 5 mg/kg/day, adjusted to maintain weekly serum level 20 mg/dL to 30 mg/dL, versus placebo. </p> </section> </section> </section> <section id="CD002053-sec-0059"> <h5 class="title">Outcomes</h5> <p>See <a href="./references#CD002053-sec-0149" title="">Characteristics of included studies</a> table for details of outcome reporting for each study. </p> <section id="CD002053-sec-0060"> <h6 class="title">Primary outcomes</h6> <p>One study reported mortality after discharge (<a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>), and one study reported mortality to discharge (<a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>). <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a> reported mortality but not according to allocated group. No study reported long‐term neurodevelopmental outcomes according to treatment group as allocated. <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a> reported the Bayley Scale of Mental Development at six months according to treatments received, not allocated. <a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a> reported short‐term neurodevelopmental and behavioural outcomes of a combined group of term and preterm infants in abstract form. The principal publication reported no neurodevelopmental data. </p> <p>Seven studies, reporting treatment failure, used a standardised score to determine response to treatment (<a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>; <a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a>; <a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a>; <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>; <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> reported need for a second agent but did not use a standardised score. One study used a standardised score, with treatment failure taken as persistence of symptoms greater than four days (<a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a>). <a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a> reported clinical seizures although criteria for seizures were not described. All infants received an EEG after administration of phenobarbital and no infant had an abnormal EEG. <a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a> reported no infant in the study had seizures. <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a> reported myoclonic jerks that were not considered seizures by the attending clinician. These are not reported as seizures in this review. <a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a> reported that infants developed myoclonic jerks with no infant being diagnosed with a clinical seizure or a seizure confirmed on EEG. <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a> reported one infant with seizure later diagnosed as a benign familial seizure. <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> reported no infant had a clinical seizure. </p> </section> <section id="CD002053-sec-0061"> <h6 class="title">Secondary outcomes</h6> <p>Secondary outcomes were all incompletely reported. The most commonly reported outcomes were days' hospitalisation by eight studies (<a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>; <a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a>; <a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a>; <a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a>; <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>; <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>), days' pharmacological treatment by six studies (<a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>; <a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a>; <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a>; <a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a>; <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>), and adverse events (treatment related) by four studies (<a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>; <a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a>; <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>; <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). </p> </section> </section> </section> <section id="CD002053-sec-0062"> <h4 class="title">Excluded studies</h4> <p>We excluded 34 studies.</p> <p>See <a href="./references#CD002053-sec-0150" title="">Characteristics of excluded studies</a> for details. </p> <section id="CD002053-sec-0063"> <h5 class="title">Ongoing studies</h5> <p>One study, comparing clonidine in addition to oral morphine versus placebo in addition to oral morphine is ongoing (<a href="./references#CD002053-bbs2-0045" title="NCT03762317. Clonidine as adjunct to morphine for neonatal abstinence syndrome [Clonidine as adjunct to morphine in the management of term and near term infants with neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT03762317 (first received 3 December 2018). ">NCT03762317</a>). </p> <p>See <a href="./references#CD002053-sec-0151" title="">Characteristics of ongoing studies</a> table for details. </p> </section> </section> </section> <section id="CD002053-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD002053-sec-0149" title="">Characteristics of included studies</a> table for risk of bias assessments and risk of bias summary (<a href="#CD002053-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD002053-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002053-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>One study, with adequate randomisation and allocation concealment, blinding of treatment and greater than 90% follow‐up on an intention‐to‐treat basis was at low risk of bias for all reported outcomes (<a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>). <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> was at low risk of bias for reporting of treatment failure, but high risk of bias for other outcomes due to incomplete outcome reporting. </p> <section id="CD002053-sec-0065"> <h4 class="title">Allocation</h4> <p>We assessed three studies at low risk of selection bias (<a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>; <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>; <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). <a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a> was at low risk of allocation concealment but did not report method of sequence generation so overall risk of selection bias was unclear. <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a> did not report allocation methods so overall risk of selection bias was unclear. We assessed five studies at high risk of selection bias (<a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a>; <a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a>; <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). <a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a> prospectively matched treatment groups first by NASS score greater than 7; if there was no match then the infant was randomly assigned although the random method was not reported. <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a> reported random allocation to treatment but did not report method of random allocation. <a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a> and <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a> communicated "drug assignment pulled from envelopes which were designated according to first letter of last name". <a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a> designated treatment according to the last number of the infant's hospital number. <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> reported random allocation but method was not reported and three infants were allocated at clinician's discretion so we assessed it at high risk. Several studies had sizeable and largely unexplained differences in the numbers of infants allocated to each group (<a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a>). <a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a> communicated that an interim analysis found the diazepam group had excessive complications (somnolence and respiratory depression), so enrolment in this group was stopped. Therefore, patient allocation in the diazepam group was non‐contemporaneous with the other groups so was at high risk of bias. </p> </section> <section id="CD002053-sec-0066"> <h4 class="title">Blinding</h4> <p>Four studies reported blinding of treatment (<a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>; <a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a>; <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a>; <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). <a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a> reported use of a saline placebo, <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a> and <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> used identical appearing solutions at a standard volume and frequency for dosing; these were at low risk of performance and detection bias. <a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a> used a placebo and a standardised regimen for titrating doses, but weekly phenobarbital levels were revealed to the treating physician so the study was at unclear risk of performance and detection bias. Three studies did not blind treatment (<a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>; <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). No other study reported blinding of treatment and given the variable treatment regimens in each of the trials, it is unlikely this was possible. </p> </section> <section id="CD002053-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies accounted for all infants (<a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>; <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>; <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>), although <a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a> excluded one infant (clonidine group) who had a seizure from the analysis of treatment failure. <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a> excluded two infants from the analysis in the clonidine group as one infant was exposed to a benzodiazepine in utero and the other infant experienced familial seizures requiring treatment with phenobarbital. <a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a> reported one postrandomisation loss. In addition, the peer‐reviewed publication did not report the preterm infants who were reported in the abstract publication. <a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a> did not  report losses so attrition bias is unclear. <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a> reported deaths of two untreated infants, but it was unclear whether this occurred before or after randomisation. One study did not report numbers entered so that any losses were unknown (<a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>). <a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a> excluded three infants from analysis (one in the phenobarbital and two in the supportive therapy groups) and seven infants had no data available for time to regain birthweight. <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> reported separately, for duration of treatment and hospital stay, one infant randomised to phenobarbital who received a second drug. <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> reported need for a second drug for all infants, but 16% did not receive the allocated intervention and other outcomes only reported in infants receiving treatment. </p> </section> <section id="CD002053-sec-0068"> <h4 class="title">Selective reporting</h4> <p>Two studies had available trial registrations and were at low risk (<a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a>; <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>). Eight studies were at unclear risk as trial registrations were not available, were retrospective, descriptions were unclear, or a combination of these. </p> </section> <section id="CD002053-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>Two studies had no other concerns including balanced groups at allocation and were at low risk of other bias (<a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a>; <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>). <a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a> reported infants in the clonidine and DTO group had significantly lower mean birthweight and was at unclear risk. Two studies reported stopping enrolment in the diazepam arm early due to an interim analysis demonstrating the possibility of adverse effects and were at unclear risk (<a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>). <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a> had asymmetric group sizes after allocation and baseline characteristics were not reported. None of the other studies provided sufficient detail of reporting to be clear about balance of groups after randomisation or other potential biases. </p> </section> </section> <section id="CD002053-sec-0070"> <h3 class="title" id="CD002053-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD002053-tbl-0001"><b>Summary of findings 1</b> Phenobarbital versus supportive care for opioid withdrawal in newborn infants</a>; <a href="./full#CD002053-tbl-0002"><b>Summary of findings 2</b> Phenobarbital versus diazepam for opioid withdrawal in newborn infants</a>; <a href="./full#CD002053-tbl-0003"><b>Summary of findings 3</b> Phenobarbital versus chlorpromazine for opioid withdrawal in newborn infants</a>; <a href="./full#CD002053-tbl-0004"><b>Summary of findings 4</b> Phenobarbital and opioid versus opioid alone for opioid withdrawal in newborn infants</a>; <a href="./full#CD002053-tbl-0005"><b>Summary of findings 5</b> Clonidine and opioid versus opioid alone for opioid withdrawal in newborn infants</a>; <a href="./full#CD002053-tbl-0006"><b>Summary of findings 6</b> Clonidine and opioid versus phenobarbital and opioid for opioid withdrawal in newborn infants</a> </p> <section id="CD002053-sec-0071"> <h4 class="title">Comparison 1. Phenobarbital versus supportive care (all infants)</h4> <p>One study compared phenobarbital versus supportive care (<a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a>). See <a href="./full#CD002053-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD002053-sec-0072"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002053-fig-0004" title="">Analysis 1.1</a>; <a href="./references#CD002053-fig-0005" title="">Analysis 1.2</a>) </p> <p><a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a> reported no evidence of a difference in treatment failure (RR 2.73, 95% CI 0.94 to 7.94; 62 participants; very low‐certainty evidence). No infant had a clinical seizure (62 participants; very low‐certainty evidence). The study did not report neonatal or infant mortality, or neurodevelopmental disability. </p> </section> <section id="CD002053-sec-0073"> <h5 class="title">Secondary outcomes</h5> <p>(<a href="./references#CD002053-fig-0006" title="">Analysis 1.3</a>; <a href="./references#CD002053-fig-0007" title="">Analysis 1.4</a>; <a href="./references#CD002053-fig-0008" title="">Analysis 1.5</a>; <a href="./references#CD002053-fig-0009" title="">Analysis 1.6</a>; <a href="./references#CD002053-fig-0010" title="">Analysis 1.7</a>) </p> <p><a href="./references#CD002053-bbs2-0007" title="KhooKT . The Effectiveness of Three Treatment Regimens Used in the Management of Neonatal Abstinence Syndrome [PhD thesis]. Melbourne (Australia): University of Melbourne, 1995. [hdl.handle.net/11343/38959]">Khoo 1995</a> reported the following for infants treated with phenobarbital compared to supportive care: an increase in days' hospitalisation (MD 20.80, 95% CI 13.64 to 27.96; 62 participants; very low‐certainty evidence), days' treatment (MD 17.90, 95% CI 11.98 to 23.82; 62 participants; very low‐certainty evidence), no evidence of a difference in time to regain birthweight (MD –1.40, 95% CI –4.07 to 1.27; 55 participants), increase in duration of stay in special care nursery (MD 23.13 days, 95% CI 15.87 to 30.39; 62 participants) and a reduction in duration of supportive care per day (MD –162.10 minutes, 95% CI –249.14 to –75.06; 62 participants). The study did not report adverse events. </p> </section> </section> <section id="CD002053-sec-0074"> <h4 class="title">Comparison 2. Phenobarbital versus diazepam (all infants)</h4> <p>Two studies compared phenobarbital versus diazepam (<a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). See <a href="./full#CD002053-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD002053-sec-0075"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002053-fig-0011" title="">Analysis 2.1</a>) </p> <p>Two studies found a reduction in treatment failure for infants treated with phenobarbital compared to diazepam (RR 0.39, 95% CI 0.24 to 0.62; 139 participants; I² = 52%; moderate heterogeneity; low‐certainty evidence) (<a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>; <a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a>). The studies did not report neonatal or infant mortality, or neurodevelopmental disability. </p> </section> <section id="CD002053-sec-0076"> <h5 class="title">Secondary outcomes</h5> <p>(<a href="./references#CD002053-fig-0012" title="">Analysis 2.2</a>; <a href="./references#CD002053-fig-0013" title="">Analysis 2.3</a>) </p> <p><a href="./references#CD002053-bbs2-0008" title="MaddenJD , ChappelJN , ZuspanF , GumpelJ , MejiaA , DavisR . Observation and treatment of neonatal narcotic withdrawal. American Journal of Obstetrics and Gynecology1977;127:199-201. [DOI: 10.1016/s0002-9378(16)33250-1] [PMID: 831502]">Madden 1977</a> reported no evidence of a difference in days' hospitalisation (MD 3.89, 95% CI –1.20 to 8.98; 32 participants; low‐certainty evidence) or days' treatment (MD 4.30, 95% CI –0.73 to 9.33; 31 participants; low‐certainty evidence). The study did not report adverse events. </p> </section> </section> <section id="CD002053-sec-0077"> <h4 class="title">Comparison 3. Phenobarbital versus diazepam (infants of mothers using only opioids)</h4> <p>One study comparing phenobarbital versus diazepam reported infants of mothers using only opioids separately (<a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>). </p> <section id="CD002053-sec-0078"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002053-fig-0014" title="">Analysis 3.1</a>) </p> <p><a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a> reported a reduction in treatment failure for infants treated with phenobarbital compared to diazepam (RR 0.55, 95% CI 0.35 to 0.85; 31 participants). The study reported no other primary outcomes. </p> </section> <section id="CD002053-sec-0079"> <h5 class="title">Secondary outcomes</h5> <p>The study reported no secondary outcomes.</p> </section> </section> <section id="CD002053-sec-0080"> <h4 class="title">Comparison 4. Phenobarbital versus diazepam (infants of mothers using opioids and other drugs) </h4> <p>One study comparing phenobarbital versus diazepam reported infants of mothers using opioids and other drugs separately (<a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a>). </p> <section id="CD002053-sec-0081"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002053-fig-0015" title="">Analysis 4.1</a>) </p> <p><a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a> reported a reduction in treatment failure for infants treated with phenobarbital compared to diazepam (RR 0.19, 95% CI 0.09 to 0.43; 76 participants). The study reported no other primary outcomes. </p> </section> <section id="CD002053-sec-0082"> <h5 class="title">Secondary outcomes</h5> <p>The study reported no secondary outcomes.</p> </section> </section> <section id="CD002053-sec-0083"> <h4 class="title">Comparison 5. Phenobarbital versus chlorpromazine (all infants)</h4> <p>Two studies compared phenobarbital versus chlorpromazine (<a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a>; <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a>. See <a href="./full#CD002053-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD002053-sec-0084"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002053-fig-0016" title="">Analysis 5.1</a>; <a href="./references#CD002053-fig-0017" title="">Analysis 5.2</a>; <a href="./references#CD002053-fig-0018" title="">Analysis 5.3</a>) </p> <p>Data from two studies found a reduction in treatment failure favouring phenobarbital (RR 0.55, 95% CI 0.33 to 0.92; 138 participants; I² = 0%; very low‐certainty evidence), and no infant had a seizure (140 participants; very low‐certainty). <a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a> reported no infant was treated with a second drug (38 participants). The studies did not report neonatal or infant mortality and neurodevelopmental disability. </p> </section> <section id="CD002053-sec-0085"> <h5 class="title">Secondary outcomes</h5> <p>(<a href="./references#CD002053-fig-0019" title="">Analysis 5.4</a>; <a href="./references#CD002053-fig-0020" title="">Analysis 5.5</a>) </p> <p><a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> reported no evidence of a difference in days' hospitalisation (MD 7.00 days, 95% CI –3.46 to 17.46; 87 participants; low‐certainty evidence) and none of 100 infants had an adverse event (low‐certainty evidence). </p> </section> </section> <section id="CD002053-sec-0086"> <h4 class="title">Comparison 6. Phenobarbital titration with loading dose versus phenobarbital titration alone (all infants) </h4> <p>One study compared phenobarbital titration with loading dose versus phenobarbital titration alone (<a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a>). </p> <section id="CD002053-sec-0087"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002053-fig-0021" title="">Analysis 6.1</a>) </p> <p><a href="./references#CD002053-bbs2-0006" title="KaltenbachK , FinneganLP . Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehavioral Toxicology and Teratology1986;8(4):353-5. [PMID: 3762845]">Kaltenbach 1986</a> reported no evidence of a difference in treatment failure (RR 1.10, 95% CI 0.59 to 2.07; 36 participants). The study did not report neonatal or infant mortality, or neurodevelopmental disability. </p> </section> <section id="CD002053-sec-0088"> <h5 class="title">Secondary outcomes</h5> <p>The study reported no secondary outcomes.</p> </section> </section> <section id="CD002053-sec-0089"> <h4 class="title">Comparison 7. Short versus long course of phenobarbital</h4> <p>One study compared short (four days) versus long (10 days) course of phenobarbital (<a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a>). </p> <section id="CD002053-sec-0090"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002053-fig-0022" title="">Analysis 7.1</a>) </p> <p><a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a> reported no evidence of a difference in treatment failure (RR 0.58, 95% CI 0.04 to 7.94; 19 participants). The study reported no other primary outcomes. </p> </section> <section id="CD002053-sec-0091"> <h5 class="title">Secondary outcomes</h5> <p>The study reported no secondary outcomes.</p> </section> </section> <section id="CD002053-sec-0092"> <h4 class="title">Comparison 8. Short versus long course of chlorpromazine</h4> <p>One study compared short (four days) versus long course (10 days) of chlorpromazine (<a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a>). </p> <section id="CD002053-sec-0093"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002053-fig-0023" title="">Analysis 8.1</a>) </p> <p><a href="./references#CD002053-bbs2-0005" title="KahnEJ , NeumannLL , PolkGA . The course of the heroin withdrawal syndrome in newborn infants treated with phenobarbital or chlorpromazine. Journal of Pediatrics1969;75(3):495-500. [DOI: 10.1016/s0022-3476(69)80281-7] [PMID: 5804200]">Kahn 1969</a> reported no evidence of a difference in treatment failure between treatment regimens (RR 3.64, 95% CI 0.52 to 25.41; 19 participants). The study did not report neonatal or infant mortality, or neurodevelopmental disability. </p> </section> <section id="CD002053-sec-0094"> <h5 class="title">Secondary outcomes</h5> <p>The study reported no secondary outcomes.</p> </section> </section> <section id="CD002053-sec-0095"> <h4 class="title">Comparison 9. Phenobarbital and opioid versus opioid alone</h4> <p>One study compared phenobarbital and DTO versus DTO alone (<a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a>). See <a href="./full#CD002053-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD002053-sec-0096"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002053-fig-0024" title="">Analysis 9.1</a>; <a href="./references#CD002053-fig-0025" title="">Analysis 9.2</a>) </p> <p><a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a> reported no treatment failure or clinical seizure in either group (20 participants; very low‐certainty evidence). </p> </section> <section id="CD002053-sec-0097"> <h5 class="title">Secondary outcomes</h5> <p>(<a href="./references#CD002053-fig-0026" title="">Analysis 9.3</a>; <a href="./references#CD002053-fig-0027" title="">Analysis 9.4</a>) </p> <p><a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a> reported a reduction in percent of time the NASS score was 8 or greater (MD –5.00, 95% CI –9.84 to –0.16; 20 participants) and days' hospitalisation (MD –43.50 days, 95% CI –59.18 to –27.82; 20 participants; low‐certainty evidence). The study reported no other outcomes. </p> </section> </section> <section id="CD002053-sec-0098"> <h4 class="title">Comparison 10. Clonidine and opioid versus opioid alone</h4> <p>One study compared clonidine and DTO versus DTO alone (<a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a>). See <a href="./full#CD002053-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD002053-sec-0099"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002053-fig-0028" title="">Analysis 10.1</a>; <a href="./references#CD002053-fig-0029" title="">Analysis 10.2</a>; <a href="./references#CD002053-fig-0030" title="">Analysis 10.3</a>) </p> <p><a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a> reported no evidence of a difference in treatment failure (RR 0.09, 95% CI 0.01 to 1.59; 80 participants; very low‐certainty evidence), although all five infants with treatment failure were in the DTO alone group. There was no evidence of a difference in seizures (RR 0.14, 95% CI 0.01 to 2.68; 80 participants; very low‐certainty evidence), although all three infants with seizures were in the DTO alone group. There was no evidence of a difference in mortality after discharge (RR 7.00, 95% CI 0.37 to 131.28; 80 participants; very low‐certainty evidence), although all three infants who died were in the clonidine and DTO group. The causes of death confirmed by autopsy were myocarditis, sudden infant death syndrome and homicide (methadone overdose). The study did not report neurodevelopmental disability. </p> </section> <section id="CD002053-sec-0100"> <h5 class="title">Secondary outcomes</h5> <p>(<a href="./references#CD002053-fig-0031" title="">Analysis 10.4</a>; <a href="./references#CD002053-fig-0032" title="">Analysis 10.5</a>; <a href="./references#CD002053-fig-0033" title="">Analysis 10.6</a>; <a href="./references#CD002053-fig-0034" title="">Analysis 10.7</a>) </p> <p><a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a> reported no evidence of a difference in days' treatment (MD –4.00 days, 95% CI –8.33 to 0.33; 80 participants; very low‐certainty evidence), maximum weight loss (MD –0.88%, 95% CI –2.33 to 0.57; 80 participants), one adverse event (supraventricular tachycardia) in the clonidine and opioid group (RR 3.00, 95% CI 0.13 to 71.51; 80 participants; very low‐certainty evidence), and seven infants in the clonidine and opioid group with rebound NAS after stopping treatment (RR 15.00, 95% CI 0.89 to 254.13; RD 0.17, 95% CI 0.05 to 0.30; 80 participants). </p> </section> </section> <section id="CD002053-sec-0101"> <h4 class="title">Comparison 11. Clonidine and opioid versus phenobarbital and opioid</h4> <p>Two studies compared clonidine and opioid versus phenobarbital and opioid (<a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a>; <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a>). <a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a> compared clonidine versus phenobarbitone in infants who had failed morphine treatment. <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a> commenced treatment of infants with NAS with clonidine and morphine versus phenobarbital and morphine. See <a href="./full#CD002053-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD002053-sec-0102"> <h5 class="title">Primary outcomes</h5> <p>(<a href="./references#CD002053-fig-0035" title="">Analysis 11.1</a>; <a href="./references#CD002053-fig-0036" title="">Analysis 11.2</a>; <a href="./references#CD002053-fig-0037" title="">Analysis 11.3</a>) </p> <p>Data from two studies found no evidence of a difference in treatment failure (RR 2.27, 95% CI 0.98 to 5.25; 93 participants; I² = 0%; very low‐certainty evidence). <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a> reported one infant in the clonidine and morphine group had a seizure (RR 3.00, 95% CI 0.13 to 71.15; 68 participants; very low‐certainty evidence) and no infant died before discharge (68 participants; very low‐certainty evidence). No studies reported neurodevelopmental disability. </p> </section> <section id="CD002053-sec-0103"> <h5 class="title">Secondary outcomes</h5> <p>(<a href="./references#CD002053-fig-0038" title="">Analysis 11.4</a>; <a href="./references#CD002053-fig-0039" title="">Analysis 11.5</a>; <a href="./references#CD002053-fig-0040" title="">Analysis 11.6</a>) </p> <p>Data from two studies found an increase in days' hospitalisation and days' treatment with phenobarbital and opioid versus clonidine and opioid (hospitalisation: MD 7.13, 95% CI 6.38 to 7.88; 91 participants; I² = 0%; low‐certainty evidence; treatment: MD 7.57, 95% CI 3.97 to 11.17; 91 participants; I² = 0%; low‐certainty evidence). There was no evidence of a difference in adverse events (RR 1.55, 95% CI 0.44 to 5.40; 93 participants; I² = 77%; high heterogeneity; very low‐certainty evidence). <a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a> reported 6/14 infants in the clonidine and morphine group experienced adverse events including hypotension, rebound hypertension and rebound NAS. <a href="./references#CD002053-bbs2-0009" title="NCT01175668. Clonidine for neonatal abstinence syndrome study [Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome]. clinicaltrials.gov/ct2/show/NCT01175668 (first received 5 August 2010). SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Comparison of clonidine versus phenobarbital as an adjunct therapy for neonatal abstinence syndrome. A prospective randomized clinical trial. Pediatric Academic Societies Annual Meeting; 2013 May 4-7; Washington, DC. 2013. SurranB , VisintainerP , ChamberlainS , KopczaK , ShahB , SinghR . Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. Journal of Perinatology2013;33(12):954-9. [DOI: 10.1038/jp.2013.95] [PMID: 23949834]">Surran 2013</a> reported 3/34 infants were oversedated in the phenobarbital and morphine group. </p> </section> </section> <section id="CD002053-sec-0104"> <h4 class="title">Other comparisons</h4> <p>There were no studies that compared diazepam and chlorpromazine.</p> </section> <section id="CD002053-sec-0105"> <h4 class="title">Comparison 12. Sensitivity analysis</h4> <p>One study, with adequate randomisation and allocation concealment, blinding of treatment and greater than 90% follow‐up on an intention‐to‐treat basis, was at low risk of bias for all reported outcomes. <a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> was at low risk of bias for reporting of treatment failure, seizures and adverse events, but high risk of bias for other reported outcomes due to incomplete outcome reporting. </p> <section id="CD002053-sec-0106"> <h5 class="title">Prespecified summary of findings outcomes</h5> <p> <ol id="CD002053-list-0019"> <li> <p><a href="./references#CD002053-bbs2-0010" title="NCT02810782. How to treat opiate withdrawal in neonates [Pharmacological treatment of narcotic neonatal withdrawal]. clinicaltrials.gov/ct2/show/NCT02810782 (first received 23 June 2016). ZimmermannU , RudinC , DuoA , HeldL , BucherHU , Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. European Journal of Pediatrics2020;179(1):141-9. [DOI: 10.1007/s00431-019-03486-6] [PMID: 31691849]">Zimmermann 2020</a> compared phenobarbital versus chlorpromazine and reported no evidence of a difference in treatment failure (RR 0.61, 95% CI 0.35 to 1.06; 100 participants), and no infant had a seizure or an adverse event in either group (100 participants). </p> </li> <li> <p><a href="./references#CD002053-bbs2-0001" title="AgtheAG , KimGR , MathiasKB , HendrixCW , Chavez-ValdezR , JanssonL , et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics2009;123(5):e849-56. [DOI: 10.1542/peds.2008-0978] [PMID: 19398463]AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. A blinded randomized clinical trial of clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for neonatal abstinence syndrome (NAS). European Journal of Pediatrics2006;165(S1):11. AgtheAG , MathiasKB , HendrixCW , JanssonL , YasterM , RoarkTR , et al. Clonidine in combination with diluted tincture of opium (DTO) versus DTO alone for opioid withdrawal in newborn infants: a blinded randomized clinical trial. In: ePAS. 2007:https://www.pas-meeting.org/past-abstracts/. LiuT , LewisT , GaudaE , GobburuJ , IvaturiV . Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. Journal of Clinical Pharmacology2016;56(8):1009-18. [DOI: 10.1002/jcph.696] [PMID: 26712409]NCT00510016. Clonidine as adjunct therapy for the treatment of neonatal abstinence syndrome (NAS). clinicaltrials.gov/ct2/show/NCT00510016 (first received 1 August 2007). XieHG , CaoYJ , GaudaEB , AgtheAG , HendrixCW , LeeH . Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology2011;51(4):502-11. [DOI: 10.1177/0091270010370587] [PMID: 20484620]">Agthe 2009</a> compared clonidine and DTO versus DTO alone and reported no evidence of a difference in treatment failure (RR 0.09, 95% CI 0.01 to 1.59; 80 participants), seizures (RR 0.14, 95% CI 0.01 to 2.68; 80 participants), mortality after discharge (RR 7.00, 95% CI 0.37 to 131.28; 80 participants), days' treatment (MD –4.00, 95% CI –8.33 to 0.33; 80 participants) or adverse events (RR 3.00, 95% CI 0.13 to 71.51; 80 participants). </p> </li> </ol> </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002053-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002053-sec-0107"></div> <section id="CD002053-sec-0108"> <h3 class="title" id="CD002053-sec-0108">Summary of main results</h3> <section id="CD002053-sec-0109"> <h4 class="title">Phenobarbital versus supportive care</h4> <p>There was very low‐certainty evidence from one study reporting outcomes of 62 infants of no difference in treatment failure from use of phenobarbital and supportive care versus supportive care alone. No infant had a clinical seizure. The study did not repot neonatal or infant mortality, neurodevelopmental disability and adverse events. There was very low certainty of evidence for a mean 21‐day increase in hospitalisation and 18‐day increase in treatment from use of phenobarbital compared to supportive care. There was no evidence of a difference in time to regain birthweight, but there was a mean 162‐minute reduction in duration of supportive care per day for infants treated with phenobarbital compared to supportive care. We were unable to extract data for severity and duration of withdrawal. </p> </section> <section id="CD002053-sec-0110"> <h4 class="title">Phenobarbital versus diazepam</h4> <p>There was low‐certainty evidence from two studies reporting outcomes of 139 infants for a reduction in treatment failure from use of phenobarbital compared to diazepam (RD –0.29, 95% CI –0.45 to –0.14; NNTB 2 to 7). The studies did not report neonatal or infant mortality, neurodevelopmental disability and adverse events. There was low‐certainty evidence from one study (32 infants) of no evidence of a difference in days' hospitalisation or days' treatment. </p> </section> <section id="CD002053-sec-0111"> <h4 class="title">Phenobarbital versus chlorpromazine</h4> <p>Very low‐certainty evidence from two studies reporting outcomes of 138 infants found a reduction in treatment failure (RD –0.19, 95% CI –0.34 to –0.03; NNTB 3 to 33) and no infant had a seizure in either group. The studies did not report neonatal or infant mortality and neurodevelopmental disability. Low‐certainty evidence from one study (87 infants) reported no evidence of a difference in days' hospitalisation and none of the 100 infants had an adverse event. </p> </section> <section id="CD002053-sec-0112"> <h4 class="title">Phenobarbital and opioid versus opioid alone</h4> <p>One study (20 infants) reported no treatment failures or clinical seizures in either group. The study did not report neonatal or infant mortality and neurodevelopmental disability. There was low‐certainty evidence from one study for a reduction in percentage of time the NASS score was 8 or greater and a mean 44 days' reduction in hospitalisation for infants treated with phenobarbital and an opioid compared to an opioid alone. The study reported no other outcomes. </p> </section> <section id="CD002053-sec-0113"> <h4 class="title">Clonidine and opioid versus opioid alone</h4> <p>Very low‐certainty evidence from one study reporting outcomes of 80 infants found no evidence of a difference in treatment failure from clonidine and DTO versus DTO alone. However, all five infants with treatment failure were in the opioid alone group. There was very low‐certainty evidence of no difference in seizures, although all three infants with seizures were in the DTO alone group. There was very low‐certainty evidence of no difference in mortality after discharge, although all three infants who died were in the clonidine and DTO group. The causes of death were not attributed to treatment. The study did not report neurodevelopmental disability. There was very low‐certainty evidence of no difference in days' treatment and maximum weight loss. One adverse event (supraventricular tachycardia) occurred in the clonidine and DTO group. Although there was no evidence of a difference in rebound neonatal abstinence syndrome after stopping treatment, all seven infants were in the clonidine and DTO group. </p> </section> <section id="CD002053-sec-0114"> <h4 class="title">Clonidine and opioid versus phenobarbital and opioid</h4> <p>Very low‐certainty evidence from two studies reporting 93 infants found no evidence of a difference in treatment failure. One study (68 infants) reported one infant in the clonidine and morphine group had a seizure and no infant died before discharge. The study did not report neurodevelopmental disability. Low‐certainty evidence from two studies found a mean seven days' increase in hospitalisation and eight days' treatment with clonidine and an opioid compared to phenobarbital and opioid. There was very low‐certainty evidence for no difference in adverse events. However, one study of clonidine versus phenobarbitone in infants who had failed morphine treatment reported 3/34 infants were oversedated in the phenobarbital and morphine group. One study of clonidine and opioid versus phenobarbital and opioid as initial treatment of neonatal abstinence syndrome reported 6/14 infants in the clonidine and morphine group experienced adverse events including hypotension, rebound hypertension and rebound NAS. </p> </section> <section id="CD002053-sec-0115"> <h4 class="title">Phenobarbital dosing</h4> <p>One study (36 infants) compared phenobarbital titration with loading dose versus phenobarbital titration alone and reported no evidence of a difference in treatment failure. The same study (19 infants) compared a short (four days) versus long (10 days) course of phenobarbital and reported no evidence of a difference in treatment failure. The study did not report neonatal or infant mortality, neurodevelopmental disability and adverse events. </p> </section> <section id="CD002053-sec-0116"> <h4 class="title">Chlorpromazine dosing</h4> <p>One study (19 infants) compared a short (four days) versus long (10 days) course of chlorpromazine and reported no evidence of a difference in treatment failure. The study did not report neonatal or infant mortality, neurodevelopmental disability and adverse events. </p> </section> </section> <section id="CD002053-sec-0117"> <h3 class="title" id="CD002053-sec-0117">Overall completeness and applicability of evidence</h3> <p>This review should be considered in the context of the associated review 'Opioid treatment for opioid withdrawal in newborn infants' (<a href="./references#CD002053-bbs2-0127" title="ZanklA , MartinJ , DaveyJG , OsbornDA . Opioid treatment for opioid withdrawal in newborn infants. Cochrane Database of Systematic Reviews (in press).">Zankl 2021</a>), which concluded "there is low certainty that the addition of an opioid increases duration of hospitalisation and treatment, but reduces days to regain birthweight and duration supportive care each day compared to supportive care alone. There is low to moderate certainty that use of an opioid reduces treatment failure compared to phenobarbital, diazepam or chlorpromazine, with low certainty of no effect on duration of hospitalisation or treatment. There is low to very low certainty for no difference in treatment failure according to type of opioid used. There is moderate certainty that buprenorphine reduces duration of hospitalisation and treatment compared to morphine. There are insufficient data to determine the effectiveness and safety of clonidine". </p> <p>This review included 10 trials enrolling 581 infants with NAS secondary to maternal opioid use in pregnancy. All studies included infants of women using other drugs in addition to an opioid, although one study excluded infants exposed to benzodiazepines in utero. There were limited data differentiating infants exposed to opioid alone versus infants exposed to an opioid and another drug, so data are applicable to populations with high rates of multiple‐drug use. All studies were conducted in high‐income counties, one each in Australia and Switzerland, and the remainder in the USA. Eight studies used a validated neonatal abstinence syndrome score (NASS or modified NASS score) to determine pharmacological treatment. One study comparing short and long courses of phenobarbital and chlorpromazine used fixed‐dosing schedules of each agent. Three studies monitored phenobarbital levels. <a href="./references#CD002053-bbs2-0002" title="BrusseauC , BurnetteT , HeidelRE . Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. Journal of Perinatology2020;40(7):1050-5. [DOI: 10.1038/s41372-020-0685-2] [PMID: 32424335]NCT03670160. Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. clinicaltrials.gov/ct2/show/NCT03670160 (first received 13 September 2018). ">Brusseau 2020</a> titrated phenobarbital dose to achieve a concentration of 25 μg/mL to 30 μg/mL, <a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a> titrated phenobarbital dose to achieve a concentration of 20 μg/mL to 30 mg/dL, and <a href="./references#CD002053-bbs2-0004" title="FinneganLP , MichaelH , LeiferB , DesaiS . An evaluation of neonatal abstinence treatment modalities. NIDA Research Monograph1984;49:282-8. [PMID: 6434973]">Finnegan 1984a</a> titrated phenobarbital dose to scores and limited increases to a level less than 70 μg/mL. All other studies titrated sedatives to NAS score without documented use of therapeutic monitoring. </p> <p>Overall, outcomes were incompletely reported for all comparisons. No studies reported neurodevelopmental outcomes for any comparison. One study (62 infants) that compared phenobarbital and supportive care versus supportive care alone reported treatment failure and duration of hospitalisation and treatment, but did not report mortality and adverse events. Two studies (139 infants) compared phenobarbital versus diazepam and reported treatment failure. Only one study reported days' hospitalisation and days' treatment and no studies reported mortality, neurodevelopmental disability and adverse events. Two studies (138 infants) compared phenobarbital versus chlorpromazine and reported treatment failure and seizures, with only one study reporting days' hospitalisation, days' treatment and adverse events. Only one study assessed Only one study reported the addition of a sedative to an opioid versus an opioid alone when commencing pharmacological treatment for NAS; the studies used phenobarbital (20 infants) and clonidine (80 infants) with reporting more complete than for other outcomes. The one study of phenobarbital and DTO versus DTO alone reported treatment failure, seizures, mortality after discharge, days' treatment and adverse events. The one study of clonidine and morphine versus morphine alone reported treatment failure, seizures, mortality to discharge, days' hospitalisation, days' treatment and adverse events. Data for severity of withdrawal (percentage of time with a NASS score of 8 or greater) were from one study of phenobarbital and DTO versus DTO alone. There were no data for growth. One study of phenobarbital versus supportive care reported days to regain birthweight. </p> <p>We prespecified the secondary outcome 'time to control of NAS (control of symptoms or reduction of NAS score to a clinically 'safe' level).' Although most studies used a NAS scoring system, severity of withdrawal from initiation of treatment was mostly unreported and no data were extractable for this outcome. <a href="./references#CD002053-bbs2-0003" title="BierJB , FergusonAE , GrenonD , MullaneE , CoyleM . The effects of phenobarbital on developmental outcomes in infants with methadone withdrawal: results of a randomized trial. Pediatric Research2000;47:175A. CoyleMG , FergusonA , LaGasseL , LiuJ , LesterB . Neurobehavioral effects of treatment for opiate withdrawal. Archives of Disease in Childhood. Fetal and Neonatal Edition2005;90:F73-4. [DOI: 10.1136/adc.2003.046276] [PMID: 15613582]CoyleMG , FergusonA , LagasseL , OhW , LesterB . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. Journal of Pediatrics2002;140(5):561-4. [DOI: 10.1067/mpd.2002.123099] [PMID: 12032522]FergusonAE , CoyleM , LaGasseL , LiuE , LesterB . Neurobehavioural effects of treatment for opiate withdrawal. Pediatric Research2001;49:18A. ">Coyle 2002</a> reported a reduction in percentage of time with a NASS score of 8 or greater after commencement of treatment from use of DTO and phenobarbital versus DTO alone (<a href="./references#CD002053-fig-0026" title="">Analysis 9.3</a>). In this review, 'treatment failure' was a surrogate for control of NAS symptoms. </p> <p>This review was limited to the comparisons stated. For comparisons of opioid versus sedative see the review 'Opioid treatment for opioid withdrawal in newborn infants' (<a href="./references#CD002053-bbs2-0127" title="ZanklA , MartinJ , DaveyJG , OsbornDA . Opioid treatment for opioid withdrawal in newborn infants. Cochrane Database of Systematic Reviews (in press).">Zankl 2021</a>). We found no randomised trial of dexmedetomidine. </p> <p>One study compared phenobarbital and supportive care versus supportive care alone. Supportive care included use of a dummy (pacifier), swaddling or close wrapping, small frequent feeds, close skin contact by carrying in sling and other methods. Other studies did not report specifics of usual or supportive care in sufficient detail to allow for subgroup analysis according to type(s) of non‐pharmacological care as prespecified. For review of non‐pharmacological care for opioid withdrawal in newborns, see <a href="./references#CD002053-bbs2-0101" title="PahlA , YoungL , Buus-FrankME , MarcellusL , SollR . Non-pharmacological care for opioid withdrawal in newborns. Cochrane Database of Systematic Reviews2020, Issue 12. Art. No: CD013217. [DOI: 10.1002/14651858.CD013217.pub2]">Pahl 2020</a>. </p> <p>Apart from comparisons of addition of a loading dose of phenobarbital and long versus short course of phenobarbital or chlorpromazine, there were no comparisons of different dosage regimens of sedatives, and there were insufficient data to allow for subgroup analyses according to dosage used. Dosage regimens are reported in the <a href="./references#CD002053-sec-0149" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD002053-sec-0118"> <h3 class="title" id="CD002053-sec-0118">Quality of the evidence</h3> <p>There was low or very low certainty of evidence for most comparisons and outcomes reported in this review with downgrading frequent for serious risk of bias and imprecision. The review was limited to 10 studies reporting 581 infants with NAS secondary to maternal opioid use in pregnancy across multiple comparisons of different sedatives and regimens, so analyses were largely underpowered to detect important differences, particularly for outcomes of lower incidence including seizures and treatment‐related adverse effects. There were limited data for use in a sensitivity analysis of studies at low risk of bias (adequate randomisation and allocation concealment, blinding of treatment and greater than 90% follow‐up on an intention‐to‐treat basis). Sensitivity analysis did not identify any statistically significant effects for treatment failure for single studies comparing phenobarbital versus chlorpromazine, and clonidine and DTO versus DTO alone for seizures, mortality after discharge, days' treatment and adverse events. </p> </section> <section id="CD002053-sec-0119"> <h3 class="title" id="CD002053-sec-0119">Potential biases in the review process</h3> <p>We performed an extensive search for published and unpublished studies to avoid publication bias, although searches of non‐English databases were not performed. At least two review authors independently assessed eligibility and risk of bias and performed data extraction. The review included studies using quasi‐random participant allocation increasing the risk of selection bias in the studies included in the review. This was addressed using a sensitivity analysis. This review prespecified the primary outcomes and comparisons, with the exception of the comparisons between phenobarbital with or without a loading dose, and long and short course sedative regimens. </p> </section> <section id="CD002053-sec-0120"> <h3 class="title" id="CD002053-sec-0120">Agreements and disagreements with other studies or reviews</h3> <p>This review should be considered in the context of the associated review 'Opioid treatment for opioid withdrawal in newborn infants' (<a href="./references#CD002053-bbs2-0127" title="ZanklA , MartinJ , DaveyJG , OsbornDA . Opioid treatment for opioid withdrawal in newborn infants. Cochrane Database of Systematic Reviews (in press).">Zankl 2021</a>). </p> <p>Several reviews have assessed the evidence for different pharmacological and non‐pharmacological treatments for infants with NAS (<a href="./references#CD002053-bbs2-0059" title="DisherT , GullicksonC , SinghB , CameronC , BoulosL , BeaubienL , et al. Pharmacological treatments for neonatal abstinence syndrome: a systematic review and network meta-analysis. JAMA Pediatrics2019;173(3):234-43. [DOI: 10.1001/jamapediatrics.2018.5044] [PMID: 30667476]">Disher 2019</a>; <a href="./references#CD002053-bbs2-0084" title="LeeJJ , ChenJ , EislerL , LiG , DavisJM , SunLS . Comparative effectiveness of opioid replacement agents for neonatal opioid withdrawal syndrome: a systematic review and meta-analysis. Journal of Perinatology2019;39(11):1535-45. [DOI: 10.1038/s41372-019-0437-3] [PMID: 31316147]">Lee 2019</a>; <a href="./references#CD002053-bbs2-0087" title="MacMillanKD , RendonCP , VermaK , RibletN , WasherDB , HolmesAV . Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pediatrics2018;172(4):345-51. [DOI: 10.1001/jamapediatrics.2017.5195] [PMID: 29404599]">MacMillan 2018</a>; <a href="./references#CD002053-bbs2-0101" title="PahlA , YoungL , Buus-FrankME , MarcellusL , SollR . Non-pharmacological care for opioid withdrawal in newborns. Cochrane Database of Systematic Reviews2020, Issue 12. Art. No: CD013217. [DOI: 10.1002/14651858.CD013217.pub2]">Pahl 2020</a>). </p> <p>One systematic review and network meta‐analysis of pharmacological treatments for neonatal abstinence syndrome included 18 trials with 1072 infants (<a href="./references#CD002053-bbs2-0059" title="DisherT , GullicksonC , SinghB , CameronC , BoulosL , BeaubienL , et al. Pharmacological treatments for neonatal abstinence syndrome: a systematic review and network meta-analysis. JAMA Pediatrics2019;173(3):234-43. [DOI: 10.1001/jamapediatrics.2018.5044] [PMID: 30667476]">Disher 2019</a>). Sublingual buprenorphine was considered the optimal treatment for a reduction in the length of treatment and length of hospital stay, but not the need for adjuvant treatment. The results were robust to bias but sensitive to imprecision. The conclusion was the current evidence suggests that buprenorphine is the optimal treatment for NAS treatment, but limitations are considerable and wide‐scale adoption requires a large multisite trial. Morphine, which is considered standard of care in most hospitals, was the lowest‐ranked opioid for length of treatment and length of hospital stay. The findings of this systematic review and network meta‐analysis are compatible with our review of an overview of direct comparisons. However, the conclusions of the review are strongly influenced by the network meta‐analysis, which includes rankings derived from direct and indirect effects, and which is sensitive to imprecision due to the relatively small number of infants included in any comparison. In addition, outcomes were limited to surrogates of treatment effect including length of treatment, length of hospital stay, need for adjuvant treatment and discontinuation of treatment for adverse events. There are no comparisons of different sedatives. </p> <p>One systematic review of RCTs and observational studies assessing the short‐term treatment outcomes of opioid pharmacotherapy for neonatal opioid withdrawal syndrome found methadone increased treatment success compared with morphine, and buprenorphine was associated with the shortest overall durations of treatment and hospitalisation (<a href="./references#CD002053-bbs2-0084" title="LeeJJ , ChenJ , EislerL , LiG , DavisJM , SunLS . Comparative effectiveness of opioid replacement agents for neonatal opioid withdrawal syndrome: a systematic review and meta-analysis. Journal of Perinatology2019;39(11):1535-45. [DOI: 10.1038/s41372-019-0437-3] [PMID: 31316147]">Lee 2019</a>). The conclusions should be treated with caution as the review was potentially biased by the inclusion of observational studies. </p> <p>One systematic review of RCTs and observational studies reviewed the evidence for rooming‐in for infants with NAS (<a href="./references#CD002053-bbs2-0087" title="MacMillanKD , RendonCP , VermaK , RibletN , WasherDB , HolmesAV . Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis. JAMA Pediatrics2018;172(4):345-51. [DOI: 10.1001/jamapediatrics.2017.5195] [PMID: 29404599]">MacMillan 2018</a>). The review found no RCTs. Review of six before‐after studies found opioid‐exposed newborns rooming‐in with mother or other family members appear to be significantly less likely to be treated with pharmacotherapy and have substantial reductions in length of hospital stay compared with those cared for in neonatal intensive care units. The conclusions should be treated with caution as the review is potentially biased by the inclusion of observational studies. </p> <p>One Cochrane Review entitle 'Non‐pharmacological care for opioid withdrawal in newborns' found six RCTs evaluating 353 infants, with four studies modifying environmental stimulation by comparing a study nursery to a regular nursery, non‐oscillating waterbeds to conventional bassinets, rocking beds to standard beds, and prone sleep positioning to supine sleep positioning (<a href="./references#CD002053-bbs2-0101" title="PahlA , YoungL , Buus-FrankME , MarcellusL , SollR . Non-pharmacological care for opioid withdrawal in newborns. Cochrane Database of Systematic Reviews2020, Issue 12. Art. No: CD013217. [DOI: 10.1002/14651858.CD013217.pub2]">Pahl 2020</a>). One study evaluated feeding practices by comparing 24 kcal/oz formula to 20 kcal/oz formula, and one study evaluated support of the mother–infant dyad by comparing tailored breastfeeding support to standard Baby‐Friendly Initiative care. The review concluded that the effect of non‐pharmacological interventions reported in the studies was uncertain due to due to risk of bias inherent in the intervention, imprecision related to study size, and heterogeneity in study design, and many prespecified outcomes were not reported. There were no RCTs of the eat, sleep, console intervention found. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002053-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Screen4Me summary diagram. RCT: randomised controlled trial." data-id="CD002053-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Screen4Me summary diagram. RCT: randomised controlled trial.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: review update" data-id="CD002053-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram: review update</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002053-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 1: Treatment failure" data-id="CD002053-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 2: Seizures" data-id="CD002053-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 2: Seizures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 3: Days' hospitalisation" data-id="CD002053-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 3: Days' hospitalisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 4: Days' pharmacological treatment" data-id="CD002053-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 4: Days' pharmacological treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 5: Time to regain birth weight (days)" data-id="CD002053-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 5: Time to regain birth weight (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 6: Duration of stay in special care nursery (days)" data-id="CD002053-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 6: Duration of stay in special care nursery (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 7: Duration of supportive care per day (minutes)" data-id="CD002053-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Phenobarbital versus supportive care (all infants), Outcome 7: Duration of supportive care per day (minutes) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus diazepam (all infants), Outcome 1: Treatment failure" data-id="CD002053-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus diazepam (all infants), Outcome 1: Treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus diazepam (all infants), Outcome 2: Days' hospitalisation" data-id="CD002053-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus diazepam (all infants), Outcome 2: Days' hospitalisation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Phenobarbital versus diazepam (all infants), Outcome 3: Days' pharmacological treatment" data-id="CD002053-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Phenobarbital versus diazepam (all infants), Outcome 3: Days' pharmacological treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Phenobarbital versus diazepam (infants of mothers using only opioids), Outcome 1: Treatment failure" data-id="CD002053-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Phenobarbital versus diazepam (infants of mothers using only opioids), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Phenobarbital versus diazepam (infants of mothers using opioids and other drugs), Outcome 1: Treatment failure" data-id="CD002053-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Phenobarbital versus diazepam (infants of mothers using opioids and other drugs), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Phenobarbital versus chlorpromazine (all infants), Outcome 1: Treatment failure" data-id="CD002053-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Phenobarbital versus chlorpromazine (all infants), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Phenobarbital versus chlorpromazine (all infants), Outcome 2: Need for second drug" data-id="CD002053-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Phenobarbital versus chlorpromazine (all infants), Outcome 2: Need for second drug </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Phenobarbital versus chlorpromazine (all infants), Outcome 3: Seizures" data-id="CD002053-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Phenobarbital versus chlorpromazine (all infants), Outcome 3: Seizures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Phenobarbital versus chlorpromazine (all infants), Outcome 4: Days' hospitalisation" data-id="CD002053-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Phenobarbital versus chlorpromazine (all infants), Outcome 4: Days' hospitalisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Phenobarbital versus chlorpromazine (all infants), Outcome 5: Adverse events" data-id="CD002053-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Phenobarbital versus chlorpromazine (all infants), Outcome 5: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Phenobarbital titration with loading dose versus phenobarbitone titration alone (all infants), Outcome 1: Treatment failure" data-id="CD002053-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Phenobarbital titration with loading dose versus phenobarbitone titration alone (all infants), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Short versus long course of phenobarbital (all infants), Outcome 1: Treatment failure" data-id="CD002053-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Short versus long course of phenobarbital (all infants), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Short versus long course of chlorpromazine (all infants), Outcome 1: Treatment failure" data-id="CD002053-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Short versus long course of chlorpromazine (all infants), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Phenobarbital and opioid versus opioid alone (all infants), Outcome 1: Treatment failure" data-id="CD002053-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Phenobarbital and opioid versus opioid alone (all infants), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Phenobarbital and opioid versus opioid alone (all infants), Outcome 2: Seizures" data-id="CD002053-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Phenobarbital and opioid versus opioid alone (all infants), Outcome 2: Seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Phenobarbital and opioid versus opioid alone (all infants), Outcome 3: Percent time Finnegan score ≥ 8" data-id="CD002053-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Phenobarbital and opioid versus opioid alone (all infants), Outcome 3: Percent time Finnegan score ≥ 8 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Phenobarbital and opioid versus opioid alone (all infants), Outcome 4: Days' hospitalisation" data-id="CD002053-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Phenobarbital and opioid versus opioid alone (all infants), Outcome 4: Days' hospitalisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 1: Treatment failure" data-id="CD002053-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 2: Seizures" data-id="CD002053-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 2: Seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 3: Mortality after discharge" data-id="CD002053-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 3: Mortality after discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 4: Days' pharmacological treatment" data-id="CD002053-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 4: Days' pharmacological treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-010.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 5: Maximum weight loss (%)" data-id="CD002053-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-010.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 5: Maximum weight loss (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-010.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 6: Adverse events (treatment‐related)" data-id="CD002053-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-010.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 6: Adverse events (treatment‐related) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-010.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 7: Rebound neonatal abstinence syndrome after stopping treatment requiring retreatment" data-id="CD002053-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-010.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.7</div> <div class="figure-caption"> <p>Comparison 10: Clonidine and opioid versus opioid alone (all infants), Outcome 7: Rebound neonatal abstinence syndrome after stopping treatment requiring retreatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-010.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Clonidine and opioid versus phenobarbital and opioid (all infants), Outcome 1: Treatment failure" data-id="CD002053-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Clonidine and opioid versus phenobarbital and opioid (all infants), Outcome 1: Treatment failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Clonidine and opioid versus phenobarbital and opioid (all infants), Outcome 2: Seizures" data-id="CD002053-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Clonidine and opioid versus phenobarbital and opioid (all infants), Outcome 2: Seizures </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Clonidine and opioid versus phenobarbital and opioid (all infants), Outcome 3: Mortality to discharge" data-id="CD002053-fig-0037" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Clonidine and opioid versus phenobarbital and opioid (all infants), Outcome 3: Mortality to discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-011.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Clonidine and opioid versus phenobarbital and opioid (all infants), Outcome 4: Days' hospitalisation" data-id="CD002053-fig-0038" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-011.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-011.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: Clonidine and opioid versus phenobarbital and opioid (all infants), Outcome 4: Days' hospitalisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-011.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-011.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Clonidine and opioid versus phenobarbital and opioid (all infants), Outcome 5: Days' pharmacological treatment" data-id="CD002053-fig-0039" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-011.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-011.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11: Clonidine and opioid versus phenobarbital and opioid (all infants), Outcome 5: Days' pharmacological treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-011.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-011.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Clonidine and opioid versus phenobarbital and opioid (all infants), Outcome 6: Adverse events (treatment‐related)" data-id="CD002053-fig-0040" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-011.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-011.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11: Clonidine and opioid versus phenobarbital and opioid (all infants), Outcome 6: Adverse events (treatment‐related) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-011.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Sensitivity analyses, Outcome 1: Treatment failure" data-id="CD002053-fig-0041" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Sensitivity analyses, Outcome 1: Treatment failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Sensitivity analyses, Outcome 2: Seizures" data-id="CD002053-fig-0042" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Sensitivity analyses, Outcome 2: Seizures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Sensitivity analyses, Outcome 3: Mortality after discharge" data-id="CD002053-fig-0043" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Sensitivity analyses, Outcome 3: Mortality after discharge</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Sensitivity analyses, Outcome 4: Days' pharmacological treatment" data-id="CD002053-fig-0044" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: Sensitivity analyses, Outcome 4: Days' pharmacological treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002053-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/urn:x-wiley:14651858:media:CD002053:CD002053-CMP-012.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Sensitivity analyses, Outcome 5: Adverse events" data-id="CD002053-fig-0045" src="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-012.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_t/tCD002053-CMP-012.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12: Sensitivity analyses, Outcome 5: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/media/CDSR/CD002053/image_n/nCD002053-CMP-012.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002053-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Phenobarbital versus supportive care for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital vs supportive care for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal </p> <p><b>Settings:</b> hospital, Australia </p> <p><b>Intervention:</b> phenobarbital vs supportive care </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Supportive care</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Phenobarbital</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.73</b> <br/>(0.94 to 7.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>62<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>321 per 1000</b><br/>(111 to 934) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal and infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 14.0 days (9.9 to 18.1)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' hospitalisation was <b>20.8 higher</b> (13.64 to 27.96 higher) in the phenobarbital group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' pharmacological treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 8.6 days (5.6 to 11.6)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' treatment was <b>17.9 higher</b> (11.98 to 23.82 higher) in the phenobarbital group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious risk of bias (quasi‐random allocation, no blinding).<br/><sup>b</sup>Downgraded one level for serious imprecision (wide confidence intervals).<br/><sup>c</sup>No events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Phenobarbital versus supportive care for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002053-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Phenobarbital versus diazepam for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital vs diazepam for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, USA<br/><b>Intervention:</b> phenobarbital vs diazepam </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Diazepam</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Phenobarbital</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b><br/>(93 to 241) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.39</b> <br/>(0.24 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/>  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal and infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 16.8 days (14.2 to 19.4)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' hospitalisation was <b>3.89 higher</b> (1.2 lower to 8.98 higher) in the phenobarbital group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' pharmacological treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 10.2 days (7.8 to 12.6)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' treatment was <b>4.3 higher</b> (0.73 lower to 9.33 higher) in the phenobarbital group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (high‐risk allocation procedures).<br/><sup>b</sup>Downgraded one level for serious inconsistency (moderate heterogeneity).<br/><sup>c</sup>Downgraded one level for serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Phenobarbital versus diazepam for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002053-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Phenobarbital versus chlorpromazine for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital vs chlorpromazine for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b>  hospital, USA and Switzerland<br/><b>Intervention:</b> phenobarbital vs chlorpromazine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Chlorpromazine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Phenobarbital</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>288 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>357 per 1000</b><br/>(219 to 587) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.55</b><br/>(0.33 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal and infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 25.0 days (16.1 to 33.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' hospitalisation was <b>7 higher</b> (3.51 lower to 17.51 higher) in the phenobarbital group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup><sup>,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' pharmacological treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/>  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (single study at low risk of bias).<br/><sup>b</sup>Downgraded one level for serious inconsistency (high heterogeneity).<br/><sup>c</sup>Downgraded one level for serious imprecision (wide confidence intervals).<br/><sup>d</sup>Downgraded two levels for very serious imprecision (no events).<br/><sup>e</sup>Downgraded one level for serious risk of bias (incomplete outcome data). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Phenobarbital versus chlorpromazine for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002053-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Phenobarbital and opioid versus opioid alone for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbital and opioid vs opioid alone for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b>  hospital, USA<br/><b>Intervention:</b> phenobarbital and opioid vs opioid alone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>D<b>ilute tincture of opium</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Phenobarbital and dilute tincture of opium</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal and infant mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 80.8 days (66.8 to 94.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' hospitalisation was <b>43.5 lower</b> (59.18 to 27.82 lower) in the phenobarbital and dilute tincture of opium group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' pharmacological treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/>  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (high‐risk allocation procedures).<br/><sup>b</sup>Downgraded two levels for very serious imprecision (single small study, no events).<br/><sup>c</sup>Downgraded one level for serious imprecision (single small study, wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Phenobarbital and opioid versus opioid alone for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002053-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Clonidine and opioid versus opioid alone for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clonidine and opioid vs opioid alone for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b>  hospital, USA<br/><b>Intervention:</b> clonidine and opioid vs opioid alone (all infants) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>D<b>ilute tincture of opium</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Clonidine and dilute tincture of opium</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/>(1 to 199) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.09</b> <br/>(0.01 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b><br/>(1 to 201) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.14</b> <br/>(0.01 to 2.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality post discharge</b> <br/>Follow‐up: 2 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7</b> <br/>(0.37 to 131.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 infants in the clonidine group died from unrelated causes.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/>  </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' pharmacological treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 15.0 days (13.0 to 17.0)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' treatment was <b>4 lower</b> (8.33 lower to 0.33 higher) in the clonidine and dilute tincture of opium group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.00</b><br/>(0.13 to 71.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 infant with supraventricular tachycardia in clonidine group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious inconsistency (single small study).<br/><sup>b</sup>Downgraded two levels for very serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Clonidine and opioid versus opioid alone for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002053-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Clonidine and opioid versus phenobarbital and opioid for opioid withdrawal in newborn infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clonidine and opioid vs phenobarbital and opioid for opioid withdrawal in newborn infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> newborn infants with opioid withdrawal<br/><b>Settings:</b> hospital, USA<br/><b>Intervention:</b> clonidine and opioid vs phenobarbital and opioid </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Phenobarbital and morphine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Clonidine and morphine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b><br/>(87 to 467) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.27</b> <br/>(0.98 to 5.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Seizures</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3</b> <br/>(0.13 to 71.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality to discharge</b> <br/>Follow‐up: 8 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neurodevelopmental disability</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 26.3 days (22.7 to 29.9)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' hospitalisation was <b>7.13 higher</b> (6.38 to 7.88 higher) in the clonidine and morphine group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Days' pharmacological treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean 24.0 days (20.4 to 27.7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean days' treatment was <b>7.57 higher</b> (3.97 to 11.17 higher) in the clonidine and morphine group </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup><sup>,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (treatment related)</b> </p> <p>To discharge</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b><br/>(29 to 360) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.55</b> <br/>(0.44 to 5.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low</b><sup>a</sup><sup>,b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported oversedation in 3 infants receiving phenobarbital and morphine.</p> <p>The other study reported 6 infants with hypotension, rebound hypertension (1 infant) and rebound NAS (1 infant) in infants treated with clonidine and morphine. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (no study at low risk of bias).<br/><sup>b</sup>Downgraded two levels for very serious imprecision (very wide confidence intervals).<br/><sup>c</sup>Downgraded two levels for very serious imprecision (single study with no events).<br/><sup>d</sup>Downgraded one level for serious imprecision (single small study with wide confidence intervals).<br/><sup>e</sup>Downgraded one level for serious inconsistency (heterogeneity, I² = 77%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Clonidine and opioid versus phenobarbital and opioid for opioid withdrawal in newborn infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/full#CD002053-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002053-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Phenobarbital versus supportive care (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [0.94, 7.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Days' hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.80 [13.64, 27.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Days' pharmacological treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.90 [11.98, 23.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Time to regain birth weight (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐4.07, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Duration of stay in special care nursery (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.13 [15.87, 30.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Duration of supportive care per day (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐162.10 [‐249.14, ‐75.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Phenobarbital versus supportive care (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002053-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Phenobarbital versus diazepam (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.24, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Days' hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.89 [‐1.20, 8.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Days' pharmacological treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.30 [‐0.73, 9.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Phenobarbital versus diazepam (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002053-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Phenobarbital versus diazepam (infants of mothers using only opioids)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.35, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Phenobarbital versus diazepam (infants of mothers using only opioids)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002053-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Phenobarbital versus diazepam (infants of mothers using opioids and other drugs)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.09, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Phenobarbital versus diazepam (infants of mothers using opioids and other drugs)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002053-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Phenobarbital versus chlorpromazine (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.33, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Need for second drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Days' hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [‐3.46, 17.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Phenobarbital versus chlorpromazine (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002053-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Phenobarbital titration with loading dose versus phenobarbitone titration alone (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.59, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Phenobarbital titration with loading dose versus phenobarbitone titration alone (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002053-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Short versus long course of phenobarbital (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.04, 7.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Short versus long course of phenobarbital (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002053-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Short versus long course of chlorpromazine (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.64 [0.52, 25.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Short versus long course of chlorpromazine (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002053-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Phenobarbital and opioid versus opioid alone (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Phenobarbital + dilute tincture of opium (DTO) vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Phenobarbital + DTO vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Percent time Finnegan score ≥ 8 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.00 [‐9.84, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 Phenobarbital + DTO vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.00 [‐9.84, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Days' hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.50 [‐59.18, ‐27.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.1 Phenobarbital + DTO vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.50 [‐59.18, ‐27.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Phenobarbital and opioid versus opioid alone (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002053-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Clonidine and opioid versus opioid alone (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 Clonidine + diluted tincture of opium (DTO) vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Clonidine + DTO vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Mortality after discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.37, 131.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 Clonidine + DTO vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.37, 131.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Days' pharmacological treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐8.33, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.1 Clonidine + DTO vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐8.33, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 Maximum weight loss (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.88 [‐2.33, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.1 Clonidine + DTO vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.88 [‐2.33, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.6 Adverse events (treatment‐related) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6.1 Clonidine + DTO vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 71.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.7 Rebound neonatal abstinence syndrome after stopping treatment requiring retreatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7.1 Clonidine + DTO vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.00 [0.89, 254.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Clonidine and opioid versus opioid alone (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002053-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Clonidine and opioid versus phenobarbital and opioid (all infants)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [0.98, 5.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 Clonidine + morphine vs phenobarbital + morphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [0.98, 5.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 71.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 Clonidine + morphine vs phenobarbital + morphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 71.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Mortality to discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.1 Clonidine + morphine vs phenobarbital + morphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 Days' hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.13 [6.38, 7.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.1 Clonidine + morphine vs phenobarbital + morphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.13 [6.38, 7.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.5 Days' pharmacological treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.57 [3.97, 11.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.1 Clonidine + morphine vs phenobarbital + morphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.57 [3.97, 11.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.6 Adverse events (treatment‐related) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.44, 5.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6.1 Clonidine + morphine vs phenobarbital + morphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.44, 5.40]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Clonidine and opioid versus phenobarbital and opioid (all infants)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002053-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Sensitivity analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 Phenobarbital vs chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.35, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.2 Clonidine + diluted tincture of opium (DTO) vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 Phenobarbital vs chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.2 Clonidine + DTO vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Mortality after discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.1 Clonidine + DTO vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.37, 131.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Days' pharmacological treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4.1 Clonidine + DTO vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.00 [‐8.33, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5.1 Phenobarbital vs chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5.2 Clonidine + DTO vs DTO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 71.51]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002053.pub4/references#CD002053-tbl-0018">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002053.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD002053-note-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD002053-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002053-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002053-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD002053-note-0015">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD002053-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD002053-note-0012">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD002053-note-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002053-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002053-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002053\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002053\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002053\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002053\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002053\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002053.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002053.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002053.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002053.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002053.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729398768"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002053.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729398772"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002053.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918edbf01a41f4a4',t:'MTc0MDcyOTM5OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 